NCDEU
New Research Approaches for Mental Health Interventions

NCDEU 51st Annual Meeting

A meeting sponsored by the American Society of Clinical Psychopharmacology (ASCP)

Anticipating the Future of Drug Development: New Targets, Integrative Biomarkers, and Beyond



June 13-16, 2011
Boca Raton Resort & Club
Boca Raton, Florida

Steering Committee Chairs: William Z. Potter, M.D., Ph.D. and Nina R. Schooler, Ph.D.
Program Committee Chairs: David J. Kupfer, M.D. and Carlos A. Zarate, M.D.

www.NCDEUMeeting.org

ASCP
American Society of Clinical Psychopharmacology

Welcome to the 51st Meeting of NCDEU – the New NCDEU

ASCP
American Society of
Clinical Psychopharmacology

On behalf of the American Society of Clinical Psychopharmacology, we are pleased to welcome you to this year's NCDEU meeting. The ASCP is proud to sponsor the meeting, now in its 51st year, which has played such a pivotal role in the development of modern-day psychopharmacology. The challenges and opportunities confronting this field have never been greater, and we are confident that the new iteration of NCDEU with increased partnership with all relevant federal agencies and the ongoing participation of researchers from academia, the pharmaceutical and biotechnology industries, as well as many other professionals engaged in various aspects of CNS research, will continue to stimulate and facilitate further progress. We are very appreciative to the members of the NCDEU Steering and Program Committees for their role in the success of the meeting.

John M. Kane, M.D.

President
American Society of Clinical Psychopharmacology

NCDEU
New Research Approaches for Mental Health Interventions

On behalf of the NCDEU Steering and Program Committees, we are delighted that you have chosen to attend this year's meeting. Last year's 50th Anniversary Meeting was a landmark event to celebrate our progress from a small gathering of investigators in a new field to a robust meeting of over 1,000 national and international researchers and staff from government, academia, industry and clinical practice. At that meeting, decisions were made that have allowed us to reinvent NCDEU – thus "the New NCDEU".

- **Organizational Changes**
  - The meeting is now formally sponsored by the American Society of Clinical Psychopharmacology (ASCP).
  - A Steering Committee with responsibility for overall organization of the meeting and a Program Committee with responsibility for evaluating submitted proposals, developing program innovations, and overseeing the meeting.
  - Collaborations with the National Institute of Health now include the National Institute of Mental Health (NIMH), National Institute of Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
  - Regulatory agency collaborations now include both the Food and Drug Administration (FDA) and the European Medicines Authority (EMA).
  - Parthenon Management Group is now ably organizing the NCDEU Meeting.
- **Program Innovations**
  - The meeting starts on Monday, June 13th with Panel Presentations, New Research Reports and a Plenary session rather than Workshops.
  - The Monday Plenary Session will be "Regulatory Perspectives on Psychiatric Drug Development from FDA and EMA."
  - The Tuesday Plenary Session will feature leadership of NIMH, NIDA and NIAAA.
  - An open forum on Wednesday titled "Pharmaceutical Pipeline Presentations" focuses on compounds in Phase 1 and Phase 2, and will be complimented by posters in the Wednesday poster session.
  - NIMH, NIDA and NIAA have organized panel sessions.
- **Program Continuities**
  - The long-standing New Investigator Program includes a workshop for the twenty (20) new investigator awardees and informal breakfast sessions.
  - NCDEU Workshops – three hour intensive and interactive sessions focused on problems and solutions will be on Tuesday & Wednesday from 3:00 pm – 6:00 pm.
  - NCDEU Reception will be from 6:00 pm – 7:30 pm on Tuesday the 14th.
  - The NCDEU Fun Run/Walk will begin at 6:45 am on Wednesday the 15th.

We hope that you will value the innovations to the meeting and the well-established traditions. NCDEU at 51 is truly a work in progress and we welcome your suggestions. Seek out any of us during the meeting, or provide your views by completing the evaluation form.

Best Regards,



William Z. Potter, M.D., Ph.D.
Steering Committee Co-Chair

Nina Schooler, Ph.D.
Steering Committee Co-Chair



David Kupfer, M.D.
Program Committee Co-Chair

Carlos Zarate, M.D.
Program Committee Co-Chair

Hotel Maps

MIZNER CENTER





Table of Contents

NCDEU
New Research Approaches for Mental Health Interventions

Featured Speakers.....5

Acknowledgements 13

Meeting Announcements.....19

Sunday, June 12, 2011 23

Monday, June 13, 2011 27

Tuesday, June 14, 2011.....39

Wednesday, June 15, 2011 51

Thursday, June 16, 2011 63

Poster Session I.....71

Poster Session II.....81

Index.....91

Notes

Regulatory Plenary

Monday, June 13th from 1:30 pm – 3:00 pm

Regulatory Perspectives on Psychiatric Drug Development from Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Manuel Haas, PharmD, MSc
European Medical Agency

Dr. Manuel Haas is Head of the Central Nervous System and Ophthalmology section in the European Medicines Agency's Safety and Efficacy Sector (Human Medicines Development and Evaluation Unit). The "CNS" Section is responsible for the management of pre- and post-authorization activities of centralized applications for marketing authorizations, and particularly the safety and efficacy part related to medicinal products in the neurology, psychiatry and ophthalmology therapeutic areas. He is a clinical pharmacist by training. He worked for several years in hospitals in France and the UK before joining the pharmaceutical industry in regulatory affairs in 2003. Following this role, he started with the European Medicines Agency in 2004 as Scientific Administrator. He has been in his current role since September 2009.

Karl Broich, M.D.
Federal Institute for Drugs and Medical Devices

Dr. Karl Broich is the Vice-President and Professor at the Federal Institute for Drugs and Medical Devices. From 1985 to 2000, Dr. Broich preformed clinical and research work at hospitals of the universities of Bonn, Halle/Saale and Philadelphia (PennU) (Board certifications in Neurology, Psychiatry, Behavioural Psychotherapy). He served as Head of the Section Neurology/ Psychiatry from 2000 to 2005 and became the department head from 2005 to 2009. Since 2009, Dr. Broich has been the deputy head (Vice-President) at the Federal Institute for Drugs and Medical Devices (BfArM) in Bonn (Germany). He also served as an alternate member of the Committee for Medicinal Products for Human Use (CHMP) from 2005 to 2009, and has served as vice-chair of CNS-Workgroup at the European Medicines Agency (EMA) since 2010. Current research activities include: clinical trials methodology CNS, biomarkers in drug development, Alzheimer's disease and other neurodegenerative disorders. He holds memberships in several learned societies of the CNS field. Dr. Broich has authored and served as a co-author for more than 90 Publications (peer reviewed articles, reviews, and book sections).

Mitchell Mathis, M.D.
Food and Drug Administration

Dr. Mitchell Mathis is the Deputy Director of Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA. He is a graduate of the Uniformed Services University of the Health Sciences School of Medicine in Bethesda, Maryland. He trained in family practice at Malcolm Grow USAF Medical Center in Maryland and in psychiatry at Walter Reed Army Medical Center in Washington, D.C. He has been practicing outpatient and emergency room psychiatry in D.C. and Maryland since 2001. He is board certified by the American Board of Psychiatry and Neurology.

Institute Directors' Plenary

Tuesday, June 14th from 8:30 am – 10:30 am

Nora Volkow, M.D.
National Institute on Drug Abuse

Dr. Nora Volkow became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May, 2003. NIDA supports most of the world's research on the health aspects of drug abuse and addiction. Her work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects of drugs and their addictive properties. Her studies have documented long lasting changes in the dopamine system affecting the actions of frontal brain regions involved with motivation, reward and inhibitory control in drug addicted subjects. She has also made important contributions to the neurobiology of obesity, ADHD, and the behavioral changes that occur with aging. Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City, where she received the Premio Robins award for best medical student of her generation. Her psychiatric residency was at New York University, where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA. She spent most of her professional career at the Department of Energy's Brookhaven National Laboratory (BNL) in Upton, New York, where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. In addition, Dr. Volkow was a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook. Dr. Volkow has published more than 475 peer-reviewed articles and more than 65 book chapters and non-peer reviewed manuscripts, and has also edited three books on the use of neuroimaging in studying mental and addictive disorders. During her professional career, she has been the recipient of multiple awards, including her selection for membership in the Institute of Medicine in the National Academy of Sciences. She was recently named one of Time Magazine's "Top 100 People Who Shape our World", and was included as one of the 20 people to watch by Newsweek magazine in its "Who's Next in 2007" feature. She was also named "Innovator of the Year" by U.S. News & World Report in 2000.

Philip Wang, M.D., Dr. P.H.
National Institute of Mental Health

Philip S. Wang, M.D., Dr.P.H. completed his undergraduate degree in biochemistry, medical school, psychiatry residency and chief residency, as well as masters and doctoral degrees in epidemiology, all at Harvard University. These training experiences impressed him with both the urgent needs as well as scientific opportunities to reduce the burdens from mental illness. In response, he has spent the majority of his professional career in research, advisory, teaching, and administrative activities, all designed to understand and improve the treatment of mental disorders. Presently, he serves as the Deputy Director of the National Institute of Mental Health (NIMH). In that role, he assists the Director in overseeing 1300 NIMH staff and $1.4 billion spent annually on basic and clinical research to transform the understanding as well as treatment of mental illnesses, and ultimately pave the way for prevention, recovery and cure. Prior to joining NIMH, Dr. Wang served on the faculty at Harvard Medical School. He conducted studies at the Brigham and Women's Hospital on the safety, effectiveness, and cost-effectiveness of psychotropic medications with grant support from NIMH, NIDA, and AHRQ. He also conducted research in the Department of Health Care Policy at Harvard Medical School to develop and test interventions that improve the treatment and functioning of people with mental disorders with grant support from NIMH and the Robert Wood Johnson Foundation. Dr. Wang is an author of approximately 160 scientific publications in leading medical journals such as the *New England Journal of Medicine*, *Journal of the American Medical Association*, and *Lancet*. Dr. Wang has served in advisory roles at both the national and international levels. He was a member of the NIMH Services and Clinical Epidemiology study section and served on other NIH Initial Review Groups. He served as a Voting Member of the Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee as well as a Deputized Voting Member of the FDA Medical Devices Advisory Committee (Neurological Devices Panel) and FDA Endocrinologic and Metabolic Drugs Advisory Committee. He also served as Chair of the World Health Organization (WHO) World Mental Health Survey Initiative's Services Research Work Group. He is currently a member of the American Psychiatric Association's (APA) *Diagnostic and Statistical Manual, Fifth Revision (DSM-V)* Task Force and has consulted on several APA Workgroups that developed evidence-based treatment guidelines. Dr. Wang actively taught throughout his time at Harvard, including mentoring residents and clinical fellows on their research projects. At the Harvard School of Public Health, he taught the Introductory Psychiatric Epidemiology course, lectured in the Advanced Pharmacoepidemiology course, and advised doctoral and master's level students.

Kenneth Warren, Ph.D.
National Institute on Alcohol Abuse and Alcoholism

Dr. Kenneth Warren is a nationally-recognized expert on alcohol and pregnancy, and a long-time senior administrator at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). He became Acting Director of NIAAA on November 1, 2008, following the retirement of Ting-Kai Li, M.D. on October 31, 2008. Dr. Li had served as NIAAA Director from September 2002 through October 2008. Dr. Warren was named as the NIAAA Deputy Director in February 2008. He joined NIAAA in 1976 as a staff member of the then Division of Research. He later became chief of the Biomedical Research Branch, and then deputy director of the Division of Extramural Research. From 1984 to 2005, he directed the Office of Scientific Affairs, whose responsibilities included peer review, grants management, committee management, scientific communications, and activities of the NIAAA National Advisory Council and Extramural Advisory Board. From 2002 to 2007, Dr. Warren served as Associate Director for Basic Research, and over the past year he has also served as acting director of the institute's Office of Science Policy and Communications. A graduate of the City College of New York, Dr. Warren earned his doctorate degree in Biochemistry from Michigan State University in 1970. He subsequently undertook postdoctoral positions at the University of California, Los Angeles and at University of Michigan Mental Health Research Institute before joining the federal government in a research position at the Walter Reed Army Institute of Research in 1974. Dr. Warren has maintained an active interest in all areas of alcohol and health and in past years often served as the editor of the triennial Reports to Congress on Alcohol and Health. He has been particularly active in research on the effects of alcohol use during pregnancy, including fetal alcohol syndrome (FAS) and fetal alcohol spectrum disorders (FASD). Dr. Warren initiated NIAAA's research program on FAS over 30 years ago. He currently chairs the government-wide Interagency Coordinating Committee on FAS. Dr. Warren has received numerous honors, including a superior service award from the Public Health Service in 1982 for his work in development of the first Surgeon General's Advisory on FAS. In 1994, Dr. Warren received the Seixas Award from the Research Society on Alcoholism (RSA). In 2002, he received the Henry Rosett Award from the Fetal Alcohol Syndrome Study Group of RSA. In 2007, the National Organization on Fetal Alcohol Syndrome (NOFAS) honored Dr. Warren by placing his name into their Tom and Linda Daschle FASD Hall of Fame, followed by the receipt of the NOFAS Excellence Award in 2008.

Economics of Drug Development Plenary

Wednesday, June 15th from 8:30 am – 11:30 am

Ernst R. Berndt, Ph.D.
MIT Sloan School of Management

Dr. Ernst R. Berndt is the Louis E. Seley Professor in Applied Economics at the MIT Sloan School of Management, and Co-Director of the Harvard-MIT Biomedical Enterprise Program. He has served as Director of the National Bureau of Economic Research Program on Technological Progress and Productivity Measurement, and until recently was Chair of the Federal Economic Statistics Advisory Committee, an interagency committee formed by the Bureau of Labor Statistics, the Bureau of Economic Analysis, and the U.S. Census Bureau. He also served as a Panel Member of the National Science Foundation Panel on Measurement, Methodology and Statistics. Currently, he serves on the Editorial Board of Health Affairs. Berndt's health care research has been published in peer-reviewed journals such as the New England Journal of Medicine, American Journal of Psychiatry, Journal of Mental Health Policy and Economics, Journal of Health Economics, and Health Affairs. In 1985, he was named the most cited economist under age 40. Professor Berndt received his Ph.D. degree in economics from the University of Wisconsin - Madison in 1972, and was awarded an honorary doctorate from Uppsala University in Sweden in 1991. He is an elected Fellow of the Econometric Society. In the last decade, much of Professor Berndt's research has focused on economic issues in health care, with a strong emphasis on measurement of costs, outcomes and prices.

Karl Broich, M.D.
Federal Institute for Drugs and Medical Devices

Dr. Karl Broich is the Vice-President and Professor at the Federal Institute for Drugs and Medical Devices. From 1985 to 2000, Dr. Broich preformed clinical and research work at hospitals of the universities of Bonn, Halle/Saale and Philadelphia (PennU) (Board certifications in Neurology, Psychiatry, Behavioural Psychotherapy). He served as Head of the Section Neurology/ Psychiatry from 2000 to 2005 and became the department head from 2005 to 2009. Since 2009, Dr. Broich has been the deputy head (Vice-President) at the Federal Institute for Drugs and Medical Devices (BfArM) in Bonn (Germany). He also served as an alternate member of the Committee for Medicinal Products for Human Use (CHMP) from 2005 to 2009, and has served as vice-chair of CNS-Workgroup at the European Medicines Agency (EMA) since 2010. Current research activities include: clinical trials methodology CNS, biomarkers in drug development, Alzheimer's disease and other neurodegenerative disorders. He holds memberships in several learned societies of the CNS field. Dr. Broich has authored and served as a co-author for more than 90 Publications (peer reviewed articles, reviews, and book sections).

Featured Speakers

Dr. med. Thomas Kaiser
Ressortleiter Arzneimittelbewertung Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Dr. Thomas Kaiser is a physician and system developer (IT-specialist). In 1990, he received a degree in System Development. He also received degree in Medicine in 1999. Dr. Kaiser is the Co-founder of the German Institute of Evidence-based Medicine (DIeM) in Cologne. He is a member of DIeM's Management Committee and Project Leader for "Drug Assessment" and "Disease Management Programmes". From 2002 to 2004, Dr. Kaiser served as an expert in working groups for Disease Management Programmes in the Coordination Committee and Federal Joint Committee. Since 2004, Dr. Kaiser has served as Head of Drug Assessment Department at IQWiG.

Joseph Parks, M.D.
Missouri Department of Mental Health
Dr. Joseph Parks serves as the Chief Clinical Officer for the Missouri Department of Mental Health in Jefferson City. He also holds the position of Distinguished Research Professor of Science at the University of Missouri – St. Louis and Director of the Missouri Institute of Mental Health. He also serves as a Clinical Assistant Professor of Psychiatry at the University of Missouri, Department of Psychiatry in Columbia. He serves as President of the Medical Director's Council of the National Association of State Mental Health Program Directors. He practices psychiatry on an outpatient basis at Family Health Center, a federally funded community health center established to expand services to uninsured and underinsured patients in the Columbia area. He recently served as the Division Director for the Division of Comprehensive Psychiatric Services for the Missouri Department of Mental Health. Dr. Parks has authored or coauthored a number of original articles, monographs, technical papers, and reviews on implementation of Evidence Based Medicine and Pharmacy Utilization Management and behavioral treatment programs. His work has appeared in several journals: *Journal of Organizational Behavior, Journal of Psychiatric Practices*, *Psychiatry Quarterly, Manual of Clinical Emergency Psychiatry, Behavioral Interviews, Hospital and Community Psychiatry,* and *Advanced Studies in Nursing.*

Husseini Manji, M.D., F.R.C.P.C.
Johnson and Johnson Pharmaceutical Research and Development

Husseini K. Manji, M.D. is Global Therapeutic Head, Neuroscience of Johnson and Johnson Pharmaceutical Research and Development. He was previously Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, NIH, and director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a visiting professor at Duke University. Dr. Manji received his B.S. (Biochemistry) and M.D. from the University of British Columbia. Following residency training, he completed fellowship training at the NIMH and obtained extensive additional training in cellular and molecular biology at the NIDDK. The major focus of his research has been the investigation of disease and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. His work has helped to conceptualize these illnesses as genetically-influenced disorders of synaptic and neural plasticity and has led to the investigation of novel therapeutics for refractory patients. He has also been actively involved in the development of biomarkers to help refine these multifactoral diseases into mechanism-based subcategories to develop targeted therapeutics. Dr. Manji is a previous recipient of numerous research awards, including: the NIMH Director‘s Career Award for Significant Scientific Achievement, the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the American College of Neuropsychopharmacology (ACNP)’s Joel Elkes award for distinguished research, the Canadian Association of Professors Award, the Brown University School of Medicine Distinguished Researcher Award, the DBSA Klerman Senior Distinguished Researcher Award, the American Federation for Aging Research Award of Distinction, and the NIMH award for excellence in clinical care and research.

Notes

Acknowledgements

NCDEU
New Research Approaches for Mental Health Interventions

Steering Committee Chairs

William Z. Potter, M.D., Ph.D.

Nina R. Schooler, Ph.D.

Program Chairs

David J. Kupfer, M.D.

Carlos A. Zarate, M.D.

New Investigator Award Program Chairs

Lauren D. Hill, Ph.D.



Mark H. Rapaport, M.D.

Poster Chair

Maurizio Fava, M.D.

Acknowledgements

Steering Committee Members

Karl Broich, M.D.
Federal Institute of Drugs and Medical Devices

Maurizio Fava, M.D.
The Massachusetts General Hospital (ASCP Board Member)

Donald Goff, M.D.
The Massachusetts General Hospital

Robert K. Heinssen, Ph.D., A.B.P.P.
National Institute of Mental Health

John M. Kane, M.D.*
The Zucker Hillside Hospital and Albert Einstein College of Medicine
(ASCP Board Member)

David J. Kupfer, M.D.
University of Pittsburgh School of Medicine

Thomas P. Laughren, M.D.
Food and Drug Administration

Raye Z. Litten, Ph.D.
National Institute of Alcohol Abuse and Alcoholism

Husseini K. Manji, M.D., F.R.C.P.C
Johnson & Johnson Pharmaceutical Research & Development

Richard K. Nakamura, Ph.D.
National Institute of Mental Health

John Newcomer, M.D.
Washington University (ASCP Board Member)

William Z. Potter, M.D., Ph.D.
Formerly of Merck & Company, Inc. (ASCP Board Member)

Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center

Philip Skolnick, Ph.D., D.Sc.
National Institute on Drug Abuse

★ Carlos A. Zarate, M.D.
National Institute of Mental Health

★New Investigator Awardee Alumnae *Representing ASCP CME Committee

Acknowledgements

NCDEU
New Research Approaches for Mental Health Interventions

New Investigator Award Program Committee

★ Cara L. Alfaro, Pharm.D.
Food and Drug Administration

★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital and Albert Einstein College of Medicine (ASCP Board Member)

Lauren D. Hill, Ph.D.
National Institute of Mental Health

Iván D. Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Mark H. Rapaport, M.D.*
Cedars-Sinai Medical Center and University of California, Los Angeles School of Medicine (ASCP Board Member)

Deidra Roach, M.D.
National Institute of Alcohol Abuse and Alcoholism

Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center

★ Holly A. Swartz, M.D.,
University of Pittsburgh School of Medicine

Program Committee

Larry Alphs, M.D., Ph.D.
Ortho-McNeil Janssen Scientific Affairs

Deanna Barch, Ph.D.
Washington University in St. Louis, Arts and Sciences

Katherine Beebe, Ph.D.
Titan Pharmaceuticals, Inc.

Alan Breier, M.D.
Indiana University Mental Health Research and Education

★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital (ASCP Board Member)

Michael Egan, M.D.
Merck & Company

★New Investigator Awardee Alumnae *Representing ASCP CME Committee

Program Committee *(continued)*

Susan Essock, Ph.D.
Columbia University, New York State Psychiatric Institute

Maurizio Fava, M.D.
Massachusetts General Hospital (ASCP Board Member)

Matthew Friedman, M.D.
Dartmouth Medical School

Judy Garber, Ph.D.
Vanderbilt University

John Greist, M.D.
Healthcare Technology Systems, Inc.

Dilip Jeste, M.D.
University of California, San Diego

Richard Keefe, Ph.D.
Duke University Medical Center

Helena Kraemer, Ph.D.
Stanford University

David J. Kupfer, M.D.
University of Pittsburgh School of Medicine

Thomas P. Laughren, M.D.
Food and Drug Administration

★ Andrew Leon, Ph.D.
Weill Cornell Medical College

★ Anil Malhotra, M.D.
The Zucker Hillside Hospital

John March, M.D., M.P.H.
Duke Clinical Research Institute

★New Investigator Awardee Alumnae *Representing ASCP CME Committee

Program Committee *(continued)*

Stephen Marder, M.D.
Semel Institute, UCLA

Craig Nelson, M.D.*
University of California San Francisco (ASCP Board Member)

Thomas Newton, M.D.
Baylor College of Medicine

★ Roy Perlis, M.D., M.Sc.
Massachusetts General Hospital

★ Katharine Phillips, M.D.
Rhode Island Hospital/Brown University

Jerrold Rosenbaum, M.D.
Massachusetts General Hospital

Bruce Saltz, M.D., P.A.
Mental Health Advocates, Inc.

Stephen Stahl, M.D.
University of California San Diego

★ Holly Swartz, M.D.
University of Pittsburgh School of Medicine

Mauricio Tohen, M.D., Dr.PH, M.B.A.
UT Health Science Center San Antonio

★ Janet Williams, D.S.W.
MedAvante

★ Kimberly Yonkers, M.D.
Yale School of Medicine

★ Carlos A. Zarate, M.D.
National Institute of Mental Health

★New Investigator Awardee Alumnae *Representing ASCP CME Committee

Notes

Meeting Services

Registration Desk Hours:

Sunday	12:00 pm – 5:00 pm
Monday	7:30 am – 5:00 pm
Tuesday	7:30 am – 6:00 pm
Wednesday	7:30 am – 6:00 pm
Thursday	7:30 am – 12:00 pm

*The registration/meeting information desk is located at the main entrance of the Mizner Center.

The NCDEU Computer Center is open on the below dates and times for attendees to briefly check emails. The Computer Center is located in the Mizner Center in the Estate Salon III.

Hours:

Sunday	12:00 pm – 5:00 pm
Monday	7:30 am – 5:00 pm
Tuesday - Wednesday	7:30 am – 6:00 pm
Thursday	7:30 am – 12:00 pm

The NCDEU Speaker Ready Room is open on the below dates and times for presenters to upload slides. The meeting organizers ask that all speakers upload their slides 24 hours prior to their scheduled presentation time. The Speaker Ready Room is located in Estate Salon II.

Sunday	12:00 pm – 5:00 pm
Monday	7:30 am – 5:00 pm
Tuesday - Wednesday	7:30 am – 6:00 pm
Thursday	7:30 am – 12:00 pm

Americans with Disabilities Act - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to info@ascpp.org.

Job Announcements may be posted on the message board at the NCDEU registration desk.

Discounts for tennis, golf and spa services are available to all NCDEU attendees and families. Call the concierge at extension 3700 for golf or tennis. The Boca Raton Resort & Club is offering all NCDEU guests a 15% discount on golf, tennis court fees and lessons. You must identify yourself as an NCDEU guest to obtain the discount. Advance reservations are recommended. The Spa Palazzo is also offering all NCDEU registrants and their families a $15.00 discount per person per day off all spa services of fifty (50) minutes or more. Advance reservations are recommended and can be made by calling 4772 from a house phone. Be sure to identify yourself as an NCDEU guest.

Continuing Education Credits

Disclosures are available for all NCDEU presenters online at www.ncdeumeeting.org.

Continuing Education Credits are available for physicians, pharmacists, psychologists, nurses and social workers. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed in the NCDEU Computer Center in Estate Salon III or after the conference at www.ncdeumeeting.org ***Surveys for continuing education credit must be submitted no later than July 15, 2011.*** There is a $40.00 administrative fee for CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Physicians

ASCP American Society of Clinical Psychopharmacology

The American Society for Clinical Psychopharmacology (ASCP) designates this live meeting for a maximum of *22 AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

ACPE®

The University of South Florida College of Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been approved for 26 contact hours. Universal program number is as follows: 0230-9999-11-008-L01-P. To receive continuing education credit, a pharmacist must attend the accredited sessions and must return the program evaluation instrument. In order to receive full credit, registrants must arrive no later than 10 minutes after the start of the meeting and must attend the entire meeting.

Psychologists

USF® HEALTH

USF Health is approved by the American Psychological Association to sponsor continuing education for psychologists. USF Health maintains responsibility for this program and its content. This program has been approved for 26 contact hours.

Nurses

The University of South Florida College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. A maximum of 26 contact hours may be earned by learners who successfully complete this continuing nursing education activity.

Social Workers

USF Health is an approved provider (BAP#433 – Exp. 3/31/13) of continuing education credits for clinical social work, marriage and family therapy, and mental health counseling. This program has been reviewed and approved for up to 31, 50-minute contact hours.

All participants who request continuing education credits by July 15, 2011, will receive their statement of credits via email by August 22, 2011.

The Meeting Evaluation Survey will be available at www.ncdeumeeting.org. We encourage all registrants to complete the evaluation. Attendees requesting CME or CE credits must complete the survey in order to obtain credits. Your candid input on the 2011 meeting is appreciated as we strive to improve the meeting each year.

NCDEU Meeting Support – The 2011 NCDEU Meeting receives no corporate funding.

NCDEU 2012 – The 52nd meeting of NCDEU will take place May 28–31, 2012 at the Arizona Biltmore in Phoenix, Arizona. Details regarding abstract submission for the 2012 will be released in September, 2011.

Notes

AT-A-GLANCE

Sunday, June 12th

8:30 am – 4:30 pm	**New Investigator Workshop (Invitation Only)** Grand Ballroom G-H
12:00 pm – 5:00 pm	**Registration Open** Mizner Center Main Entrance

Notes

8:30 am – 4:30 pm ***Grand Ballroom G-H***
New Investigator Workshop (Invitation Only)

Co-Chairs: Mark H. Rapaport, M.D., Cedars-Sinai Medical Center and University of California, Los Angeles School of Medicine
Lauren D. Hill, Ph.D., National Institute of Mental Health

The NCDEU meeting offers a special program for new investigators in an effort to promote the education and training of junior investigators in psychopharmacology. Established investigators were asked to nominate individuals who may be interested in a research career in psychopharmacology for this special program. These nominees submitted an abstract describing their current research or area of research interest, a letter of recommendation from their chair or mentor, a career statement and a curriculum vitae. The selection of awardees was based upon the scientific merit of the abstract, the level of training of the nominee and a committee of internal and external reviewers' assessment of the relative value of the specialized program to each applicant at this time in his/her career. The awardees will participate in this special educational workshop and present their posters during the scheduled poster sessions. In addition, they will receive a travel expense award and a certificate acknowledging their participation in the program at an award ceremony on Monday evening, June 13th. This year's 20 New Investigator awardees are indicated with a ribbon in the poster section of this program.

Faculty

Mark T. Bunker, Pharm.D., B.C.P.P.
Cyberonics, Inc.

Tiffany R. Farchione, M.D.
US Food and Drug Administration

Lauren D. Hill, Ph.D.
National Institute of Mental Health

Andrew C. Leon, Ph.D.
Weill Medical College of Cornell University

Raye Z. Litten, Ph.D.
National Institute on Alcohol Abuse and Alcoholism

Iván D. Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Mark H. Rapaport, M.D.
Cedars-Sinai Medical Center and University of California, Los Angeles School of Medicine

Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center

Holly A. Swartz, M.D.
University of Pittsburgh School of Medicine

New Investigator Awardees

Chadi Abdallah, M.D.
SUNY Downstate Medical Center

Rivi Ben Dor, M.D.
NIMH

Jatinder Chawla, M.D.
SUNY Downstate Medical Center

Arman Danielyan, M.D.
Cincinnati Children's Hospital Medical Center

Marta Hauser, Ph.D.
The Zucker Hillside Hospital, North Shore Long Island Jewish Medical Center

Styliani Kaliora, M.D.
The Zucker Hillside Hospital

Taishiro Kishimoto, M.D., Ph.D.
The Zucker Hillside Hospital

Maju Koola, M.D., D.P.M.
Maryland Psychiatric Research Center, University of Maryland School of Medicine

Fernanda Laezza, M.D., Ph.D.
UTMB

Tara Lauriat, Ph.D.
St. Elizabeth's Medical Center

Nadia Iovieno, M.D.
MGH, Depression Clinic and Research Program

Erin McGlade, Ph.D.
University of Utah Brain Institute

Jimmi Nielsen, M.D., Ph.D.
Aalborg Psychiatric Hospital

Chad Rethorst, Ph.D.
University of Texas - Southwestern Medical Center

Amar Sahay, Ph.D.
Columbia University

Manpreet Singh, M.D., M.S.
Stanford University School of Medicine

Luke Stoeckel, Ph.D.
Harvard/MGH

Walter Swardfager, MSc
Sunnybrook Health Sciences Centre

Jeremy Veenstra-VanderWeele, M.D.
Vanderbilt University

Jennice Vilhauer, Ph.D.
Cedars-Sinai Medical Center

AT-A-GLANCE

Monday, June 13th

7:30 am – 8:30 am **New Investigator Awardee Roundtable Breakfast (Invitation Only)**
Veranda Salon IV

7:30 am – 9:00 am **Continental Breakfast**
Grand & Royal Palm Assemblies (Mizner Center)

8:30 am – 9:00 am **Conference Opening**
Grand Ballroom A-E

9:00 am – 10:30 am **Concurrent Panel Sessions**

NIAAA Panel - Personalized Medicine: Genetic Polymorphisms and Medications	***NIDA Panel - Magic Bullets and Arrows: Biologics to Treat Substance Use Disorders***	***NIMH Panel - Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC)***
Location: Grand Ballroom G-H	Location: Grand Ballroom I-J	Location: Royal Palm Salon II-IV

10:30 am – 10:45 am **Coffee Break**
Grand/Royal Palm Assemblies (Mizner Center)

10:45 am – 11:45 am **Concurrent Individual Research Reports**

Late Breaking Research Reports 1	***Late Breaking Research Reports 2***	***Late Breaking Research Reports 3***
Location: Grand Ballroom G-H	Location: Grand Ballroom I-J	Location: Royal Palm Salon II-IV

11:45 am – 1:30 pm **Lunch on own**

1:30 pm – 3:00 pm **Plenary - *Regulatory Perspectives on Psychiatric Drug Development from Food and Drug Administration (FDA) and European Medicines Agency (EMA)***
Grand Ballroom A-E

3:00 pm – 3:15 pm **Coffee Break**
Grand/Royal Palm Assemblies

3:15 pm – 4:45 pm **Concurrent Individual Research Reports**

Research Reports – Schizophrenia	***Research Reports – Methodological Innovations***	***Research Reports – Depression***
Location: Grand Ballroom G-H	Location: Grand Ballroom I-J	Location: Royal Palm Salon II-IV

6:00 pm – 7:30 pm **New Investigator Award Ceremony & Reception (Invitation Only)**
Addison West Ballroom

7:30 am – 8:30 am ***New Investigator Awardee Roundtable Breakfast (Invitation Only)***
Veranda Salon IV

7:30 am – 9:00 am ***Continental Breakfast***
Grand/Royal Palm Assemblies (Mizner Center)

8:30 am – 9:00 am ***Conference Opening***
Grand Ballroom A-E

Panel Sessions

9:00 am – 10:30 am ***NIAAA Panel - Personalized Medicine: Genetic Polymorphisms and Medications***
Grand Ballroom G-H

Chairs: Antonio Noronha, Ph.D.
National Institute on Alcohol Abuse and Alcoholism
Raye Litten, Ph.D.
National Institute on Alcohol Abuse and Alcoholism

9:00 am – 9:25 am **Pharmacogenetic Approach at the Serotonin Transporter Gene as a Method to Reduce Severe Alcohol Consumption**
Bankole Johnson, Sc.D., M.D., Ph.D., University of Virginia

9:25 am – 9:50 am **Pharmacogenetics of Mu Opioid Receptor Gene Polymorphisms for Alcohol Dependence**
David Oslin, M.D., University of Pennsylvania

9:50 am – 10:15 am **Pharmacogenomics of Alcohol and Alcohol Pharmacotherapies Studied in the Human Laboratory**
Robert Swift, M.D., Ph.D., Brown University

10:15 am – 10:30 am **General Discussion**

9:00 am – 10:30 am ***NIDA Panel - Magic Bullets and Arrows: Biologics to treat Substance Use Disorders***
Grand Ballroom I-J

Chairs: Jane B. Acri, Ph.D., National Institute on Drug Abuse
David McCann, Ph.D., National Institute on Drug Abuse

9:00 am – 9:25 am **Vaccines for Cocaine Dependence**
Thomas Kosten, M.D., Baylor College of Medicine

9:25 am – 9:50 am **Engineered ButyrylCholinesterase for Cocaine Addiction Treatment**
Merav Bassan, Ph.D., TEVA Pharmaceutical Industries

9:50 am – 10:15 am **Safety and Efficacy of the Nicotine Vaccine (NicVAX) for Smoking Cessation**
Raafat Fahim, Ph.D., Nabi Biopharmaceuticals

10:15 am – 10:30 am **General Discussion**

9:00 am – 10:30 am ***NIMH Panel - Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC)***
Royal Palm Salon II-IV

Chair: Benedetto Vitiello, M.D., National Institute of Mental Health

9:00 am – 9:05 am **Introduction**
Benedetto Vitiello, M.D., National Institute of Mental Health

9:05 am – 9:30 am **Rationale and Selection of Interventions and Outcome Variables**
Madhukar Trivedi, M.D., University of Texas Southwestern

9:30 am – 9:55 am **EMBARC Design and Methods**
Patrick McGrath, M.D., New York State Psychiatric Institute

9:00 am – 10:30 am (continued)	***NIMH Panel - Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC)*** ***Royal Palm Salon II-IV***
9:55 am – 10:20 am	**Analytical Approach to EMBARC Data** Eva Petkova, Ph.D., New York University School of Medicine
10:20 am – 10:30 am	**General Discussion**
10:30 am – 10:45 am	***Coffee Break*** ***Grand/Royal Palm Assemblies (Mizner Center)***

Individual Research Reports

10:45 am – 11:45 am	***Late Breaking Research Reports 1*** ***Grand Ballroom G-H***

Chair: Jerrold Rosenbaum, M.D., Massachusetts General Hospital

10:45 am – 11:00 am	**Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?** Richard Keefe, M.D., Duke University Medical Center
11:00 am – 11:15 am	**Reducing the Effect of Drug Company Promotion** Jeffrey Mattes, M.D., Psychopharmacology Research Association of Princeton
11:15 am – 11:30 am	**Double-Blind Study of Quetiapine for the Treatment of Cocaine Dependence** Andre Tapp, M.D., VA Puget Sound Health Care System
11:30 am – 11:45 am	**Clinically Unintended Medication Switches and Inability to Prescribe Preferred Medications Under Medicare Part D** Darrel Regier, M.D., M.P.H., American Psychiatric Institute

10:45 am – 11:45 am ***Late Breaking Research Reports 2***
Grand Ballroom I-J

Chair: Holly Swartz, M.D., University of Pittsburgh School of Medicine*

10:45 am – 11:00 am **Regulatory Requirements on Biomarkers for Drug Development: an EU Perspective**
Karl Broich, M.D., Federal Institute for Drugs and Medical Devices, Bonn, Germay

11:00 am – 11:15 am **Quantitative Assessment of Beta-Amyloid Aggregation with Florbetapir F18 PET as a Biomarker for MCI and AD Trials**
P. Murali Doraiswamy, M.D., Duke University*

11:15 am – 11:30 am **Characterization of the Lorazepam Dose-Response Relationship using resting-state Magnetoencephalography (MEG) and Electroencephalography (EEG)**
Todd A. Verdoorn, Ph.D., Orasi Medical

11:30 am – 11:45 am **A Novel Method to Monitor Medication Adherence and Physiologic Parameters in Psychiatric Patients Using Ingestible Markers: Early Clinical Experience**
John Kane, M.D., The Zucker Hillside Hospital

***New Investigator Awardee Alumni**

10:45 am – 11:45 am ***Late Breaking Research Reports 3***
Royal Palm Salon II-IV

Chair: Katherine Beebe, Ph.D., Titan Pharmaceuticals, Inc.

10:45 am – 11:00 am **Placebo-Related Response in Clinical Trials for Bipolar Mania: What is Driving this Phenomenon and What Can be Done to Minimize it?**
Aysegul Yildiz, M.D., Dokuz Eylül University

11:00 am – 11:15 am **Affective Instability in Maintenance Treatment of Bipolar I and II Depression**
Vivek Singh, M.D., UTHSCSA

11:15 am – 11:30 am **Adjunctive Risperidone Treatment for Antidepressant-Symptoms of Chronic Military Service-Related PTSD: Findings of VA Cooperative Study #504**
John Krystal, M.D., VA National Center for PTSD, Yale University School of Medicine & VA Connecticut Healthcare System

11:30 am – 11:45 am **The Remission from Depression Questionnaire**
Mark Zimmerman, M.D., Rhode Island Hospital

11:45 am – 1:30 pm ***Lunch on own***

Plenary

1:30 pm – 3:00 pm ***Regulatory Perspectives on Psychiatric Drug Development from Food and Drug Administration (FDA) and European Medicines Agency (EMA) Grand Ballroom A-E***

Chairs: Mitchell Mathis, M.D., Food and Drug Administration
Karl Broich, M.D., Federal Institute of Drugs and Medical Devices, Bonn, Germany

Psychiatric drug development has become multinational and pharmaceutical sponsors must operate in a multinational regulatory framework. This session will provide perspectives from regulators representing FDA and EMA. Karl Broich, representing EMA, is Vice President of the German BfArM and Deputy Chair of the CNS Working Group at EMA**,** and Mitchell Mathis, representing FDA, is Director of the Division of Psychiatry Products. Each regulator will provide a very brief introduction to the agency each represents, and then provide a perspective on a few selected regulatory issues that are common to all regulatory agencies. Each regulator will have roughly 30 minutes to provide formal comments, and the session will then continue for the final 30 minutes with a more informal discussion with the audience on these selected issues as well as other regulatory matters of common interest to the group. The goal of the session will not be to achieve consensus on regulatory issues, but rather, to gain insight and understanding of similarities and differences in how FDA and EMA address drug development matters of common interest.

1:30 pm – 1:45 pm **The European Medicines Agency and the Centralized Procedure for Drug Approval**
Manuel Haas, PharmD, MSc, Head of the Central Nervous System and Ophthalmology Section in the European Medicines Agency

1:45 pm – 2:15 pm **FDA Perspective on Selected Regulatory Issues Pertinent to Psychiatric Drug Development**
Mitchell Mathis, M.D., Food and Drug Administration

2:15 pm – 2:45 pm **EMA Perspective on Selected Regulatory Issues Pertinent to Psychiatric Drug Development**
Karl Broich, M.D., Federal Institute of Drugs and Medical Devices, Bonn, Germany

2:45 pm – 3:00 pm **General Discussion**

Individual Research Reports

3:15 pm – 4:45 pm ***Research Reports – Schizophrenia***
Grand Ballroom G-H

Chair: Donald Goff, M.D., Massachusetts General Hospital

3:15 pm – 3:30 pm **Pioglitazone as a Treatment for Glucose and Lipid Abnormalities in Schizophrenic Patients: A Double–Blind Placebo Controlled Study**
Robert Smith, M.D., Ph.D., NYU Medical School and NKI

3:30 pm – 3:45 pm **Oxytocin Treatment Improves Social Cognition and Reduces Psychotic Symptoms in Schizophrenia**
Cort A. Pedersen, M.D., University of North Carolina School of Medicine

3:45 pm – 4:00 pm **Using EEG, PET and Other Early Pharmacodynamic Data to Inform Dose Selection in the Clinical Development of ITI-007**
Kimberly E. Vanover, Ph.D., Intra-Cellular Therapies, Inc.

4:00 pm – 4:15 pm **More Efficient Drug Discovery Trials in Schizophrenia: Insights from 29 Placebo-Controlled RCTs of Second-Generation Antipsychotics in the NEWMEDS Repository**
Jonathan Rabinowitz, Ph.D., Bar Ilan University

4:15 pm – 4:30 pm **Long-term Efficacy and Effectiveness of Antipsychotic Medication for Schizophrenia, a Data-driven Personalized, Clinical Approach**
Ira D. Glick, M.D., Stanford University School of Medicine

4:30 pm – 4:45 pm **Low Dose Naltrexone for Antipsychotic Induced Weight Gain in Women with Schizophrenia**
Cenk Tek, M.D., Yale University School of Medicine

3:15 pm – 4:45 pm ***Research Reports – Methodological Innovations***
Grand Ballroom I-J

Chair: Deanna Barch, Ph.D., Washington University

3:15 pm – 3:30 pm **The Usefulness of Positive Controls and Active Comparators in Proof of Concept Trials**
Craig Mallinckrodt, M.D., Eli Lilly & Company

3:30 pm – 3:45 pm **Five Alternative Assessment Methods to Determine Patient Eligibility in CNS Trials**
Steven D. Targum, M.D., Clintata, LLC

3:45 pm – 4:00 pm **Prospective Assessment and the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS): Using Technology to Improve Precision for Risk Estimation and Safety Monitoring, Optimize Data Collection, and Decrease Burden**
Kelly L. Posner, Ph.D., Columbia University

4:00 pm – 4:15 pm **Now You See It, Now You Don't: Challenges in Measuring Hostility and Aggression**
Leslie Citrome, M.D., Nathan S Kline Institute for Psychiatric Research

4:15 pm – 4:30 pm **Computer Administered Scales: View from a Third Blind Eye**
Gary S. Sachs, M.D., Massachusetts General Hospital & United BioSource Corporation

4:30 pm – 4:45 pm **Issues in Training and Surveillance of Raters in CNS Clinical Trials**
David G. Daniel, M.D., United Biosource Corporation

3:15 pm – 4:45 pm	***Research Reports – Depression*** ***Royal Palm Salon II-IV***

Chair: Craig Nelson, M.D., University of California, San Francisco

3:15 pm – 3:30 pm	**Compound Identified by Neurogenesis Platform Shows Promising Efficacy in Treatment of Patients with Major Depressive Disorder (MDD) with Concomitant Generalized Anxiety Disorder (GAD)** Allan H. Young, M.D., Ph.D., University of British Columbia
3:30 pm – 3:45 pm	**L-methylfolate Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) for Major Depressive Disorder: Results of Two Randomized, Double-Blind Trials** George Papakostas, M.D., Massachusetts General Hospital and Harvard Medical School*
3:45 pm – 4:00 pm	**Pilot Study of Paroxetine to Prevent Development of Depression in Primary Brain Tumor Patients** Elana Farace, Ph.D., Penn State University College of Medicine
4:00 pm – 4:15 pm	**Duloxetine vs. Placebo in the Treatment of Non-Major Chronic Depressive Disorder** David J. Hellerstein, M.D., Columbia University
4:15 pm – 4:30 pm	**Efficacy and Safety of OPC-34712, a Novel Psychotropic, as Adjunctive Treatment for Major Depressive Disorder** Michael E. Thase, M.D., University of Pennsylvania
4:30 pm – 4:45 pm	**Impact of Agreement between Clinician and Patient Ratings of Symptom Severity and Anxiety on Response to Antidepressant Treatment in Major Depressive Disorder** Boadie W. Dunlop, M.D., Emory University School of Medicine*
6:00 pm – 7:30 pm	***New Investigator Awards Ceremony & Reception – Led by Mark Rapaport and Lauren Hill (Invitation Only)*** ***Addison West Ballroom***

***NCDEU New Investigator Awardee Alumnae**

Notes

AT-A-GLANCE

Tuesday, June 14th

7:00 am – 8:30 am **ASCP Board Meeting**
Royal Palm Salon I

7:30 am – 8:30 am **New Investigator Awardee Roundtable Breakfast (Invitation Only)**
Veranda Salon IV

7:30 am – 9:00 am **Continental Breakfast**
Grand & Royal Palm Assemblies (Mizner Center)

8:30 am – 10:30 am **Plenary – NIMH, NIDA & NIAAA Institute Directors**
Grand Ballroom A-E

10:30 am – 10:45 am **Coffee Break**
Grand/Royal Palm Assemblies (Mizner Center)

10:45 am – 12:15 pm **Concurrent Panel Sessions**

Long Term Treatment in Schizophrenia: The NIMH PROACTIVE Study	***Cross-Cutting Dimensional Assessment for Diagnostic Syndromes***	***Update on Child and Adolescent Psychopharmacologic Treatment Patterns and Safety in Community Practice: Evidence from Medicaid Datasets***
Location: Grand Ballroom G-H	Location: Grand Ballroom I-J	Location: Royal Palm Salon II-IV

12:30 pm – 2:30 pm **Poster Session I with Box Lunches**
Royal Palm V-X

2:45 pm – 5:45 pm **Concurrent Workshops**

Developing Dynamic, Sequential Treatments that Optimize Mental Health Outcomes: Novel Clinical Trial Design and Data Analysis Strategies	***Evidence-Based Evaluation and Treatment of Youth with Maladaptive Aggression***	***The Risks and Benefits of Including Suicidal Patients in Clinical Trials: Scientific, Ethical, and Regulatory Perspectives***	***The Automation of Cognitive Testing in Clinical Trials***
Location: Grand Ballroom G-H	Location: Grand Ballroom I-J	Location: Royal Palm Salon II-IV	Location: Addison Ballroom

4:15 pm – 4:30 pm **Break During Workshops**

6:00 pm – 7:30 pm **NCDEU Reception**
Garden Pool

7:00 am – 8:30 am ***ASCP Board Meeting***
Royal Palm Salon I

7:30 am – 8:30 am ***New Investigator Awardee Roundtable Breakfast (Invitation Only)***
Veranda Salon IV

7:30 am – 9:00 am ***Continental Breakfast***
Grand/Royal Palm Assemblies (Mizner Center)

Plenary Session

8:30 am – 10:30 am ***Plenary – NIMH, NIDA & NIAAA Institute Directors***
Grand Ballroom A-E

Chair: David J. Kupfer, M.D., University of Pittsburgh School of Medicine
NCDEU 2011 Program Committee Chair

8:30 am – 9:00 am ***Developing the Next Generation of Treatments for Mental Disorders***
Phillip S. Wang, M.D., National Institute of Mental Health

Monoamines have been long-standing therapeutic targets due to early, often serendipitous, clinical observations of their usefulness in the treatment of mental disorders. Although this focus has yielded our current medications and even some new therapeutic strategies, the treatment armamentarium is far from sufficient. Fortunately, discoveries in genomics and neuroscience are beginning to elucidate the neurobiological bases underlying mental illnesses. Many of these offer promising translational opportunities. This presentation will provide an overview of recent research findings illustrating potential new therapeutic targets at the genetic, epigenetic, molecular, cellular, and circuit levels. Recent efforts at the National Institute of Mental Health to foster the development of new efficacious, safe, and personalized treatments for mental disorders will also be discussed.

8:30 am – 10:30 am (continued)	***Plenary – NIMH, NIDA & NIAAA Institute Directors Grand Ballroom A-E***

9:00 am – 9:30 am

Frontiers of Medications for Addiction
Nora D. Volkow, M.D., National Institute of Drug Abuse

Neuroscientific discoveries over the past decade have enriched our understanding of the neurobiological mechanisms underlying addiction. This research has identified new molecular mechanisms and processes as potential targets for pharmacotherapies for addiction. For example, findings from genetics that have shown that the nicotine alpha 5 and beta 3 receptors may be involved in nicotine addiction suggest that compounds that interact with these receptors may be beneficial for smoking cessation. Our understanding of the neuroplastic changes that occur with addiction including modification to dopamine signaling (D1, D2 and D3 receptors) and glutamate neurotransmission (NMDA and AMPA, receptors, glutamate transporters) and of the neuronal pathways affected such as prefrontal networks involved with executive function have also identified promising new approaches to aim at reverting drug induced changes. In parallel, advances in vaccine technology have now made it feasible to develop vaccines that target specific drugs of abuse as is the case for the nicotine and cocaine vaccine which are currently being tested in humans subjects. Finally, clinical studies are also starting to reveal the potential of slow release formulations (ie naltrexone, biuprenorphine) or of medication combinations (veranicline + bupropion) as more effective strategies for the treatment of substance use disorders. However, translation of these potential medications into the clinic will require a stronger partnership between public and private efforts.

8:30 am – 10:30 am (continued)	***Plenary – NIMH, NIDA & NIAAA Institute Directors Grand Ballroom A-E***

9:30 am – 10:00 am ***Advances in Medications Development to Treat Alcohol Dependence***
Kenneth Warren, Ph.D., National Institute of Alcohol Abuse and Aging

Efforts to develop medications for Alcohol Use Disorders (AUD) have expanded rapidly in recent years. So far, four medications have been approved by the FDA for alcoholism treatment. However, because of the heterogeneous nature of AUD, many patients have limited or no response to these medications. Therefore, developing new medications is important step in providing treatment to a greater number of patients. Identification of more effective targets for drug development of alcohol dependence requires a better understanding of the elements that encompass multiple aspects of dependence. Currently, there are many promising targets being investigated. Studies are also underway to improve the tools for drug development. These include validating screening models using animal and human lab paradigms to predict clinical performance, optimizing the methodology of alcohol clinical trials, and discovering and developing alcohol biomarkers. A network of clinical sites, called the NIAAA Clinical Investigations Group (NCIG), has been established to conduct proof of concept trials on promising medications. NCIG has a quick turnaround time using a pharmaceutical model of operation. In addition, over 30 Phase 2 pharmacotherapy trials are supported studying a variety of agents in various AUD populations, including the understudied populations of psychiatric and substance abuse comorbidity, comorbid medical disorder, and adolescent/young adults. Finally, progress has been made in advancing personalized medicine. For example, in recent studies, polymorphisms of several genetic sites have been shown to influence responses to several medications, including naltrexone and ondansetron. Our goal, over the next decade, is to make the translational process of drug development, from drug discovery and preclinical testing to human studies to implementation in real-world treatment settings, more efficient and effective. In carrying out this goal, it is essential to establish collaborative networks and partnerships among government, academia, pharmaceutical industry, healthcare organizations, and advocacy groups.

10:00 am – 10:30 am **General Discussion**

10:30 am – 10:45 am ***Coffee Break***
Grand/Royal Palm Assemblies (Mizner Center)

Panel Sessions

10:45 am – 12:15 pm ***Long Term Treatment in Schizophrenia: The NIMH PROACTIVE Study***
Grand Ballroom G-H

Chair: Nina R. Schooler, Ph.D., The Zucker Hillside Hospital

10:45 am – 10:50 am **Introduction**
Nina R. Schooler, Ph.D., The Zucker Hillside Hospital

10:50 am – 11:10 am **The PROACTIVE Study: Innovations in Design and Assessment**
Nina R. Schooler, Ph.D., The Zucker Hillside Hospital

11:10 am – 11:30 am **The PROACTIVE Study Cohort: Characterization and Baseline Symptoms**
John Lauriello, M.D., University of Missouri School of Medicine

11:30 am – 11:50 am **Initial Results: Time to Relapse Comparison Between LAI and Oral Second-Generation Anti-Psychotics**
Peter F. Buckley, M.D., Georgia Health Sciences University

11:50 am – 12:00 pm **Discussant**
Joseph P. McEvoy, M.D., Duke University School of Medicine

12:00 pm – 12:15 pm **General Discussion**

10:45 am – 12:15 pm ***Cross-Cutting Dimensional Assessment for Diagnostic Syndromes***
Grand Ballroom I-J

Chair: Darrel A. Regier, M.D., MPH, American Psychiatric Association

10:45 am – 10:55 am **Introduction**
Darrel A. Regier, M.D., MPH, American Psychiatric Association

10:55 am – 11:15 am **Adoption and Use of Adult Dimensional Measures for Diagnosis in DSM-5**
Jack D. Burke, M.D., The Cambridge Health Alliance

10:45 am – 12:15 pm (continued)	***Cross-Cutting Dimensional Assessment for Diagnostic Syndromes*** ***Grand Ballroom I-J***
11:15 am – 11:35 am	**Adoption and Use of Child and Adolescent Dimensional Measures for Diagnosis in DSM-5** David Shaffer, M.D., NYSPI and Columbia University
11:35 am – 11:55 am	**Considerations for Dimensional Assessment of Disability Among Psychiatric Diagnoses** William E. Narrow, M.D., MPH, American Psychiatric Association
11:55 am – 12:15 pm	**General Discussion**

10:45 am – 12:15 pm	***Update on Child and Adolescent Psychopharmacologic Treatment Patterns and Safety in Community Practice: Evidence from Medicaid Datasets*** ***Royal Palm Salon II-IV***

Chair: Julie M. Zito, Ph.D., University of Maryland

10:45 am – 11:00 am	**Trends in Antipsychotic Use (1997-2006) Among Medicaid-Insured Youth** Julie M. Zito, Ph.D., University of Maryland
11:00 am – 11:15 am	**Simulating RCT Results Using Longitudinal, Observational Data Sets to Estimate the Safety of Second Generation Antipsychotics in Pediatric Patients** Jeanette Jerrell, Ph.D., University of South Carolina School of Medicine
11:15 am – 11:30 am	**Concomitant Antipsychotic Use among Youth Continuously Enrolled in Medicaid** Susan dosReis, Ph.D., University of Maryland*
11:30 am – 11:45 am	**Assessing Drug Safety in Concomitant Therapy for ADHD: Medicaid Data and Design Issues** Almut Winterstein, Ph.D., University of Florida
11:45 am – 11:55 am	**Discussion** Benedetto Vitiello, M.D., National Institute of Mental Health
11:55 am – 12:15 pm	**Audience Participation**

***NCDEU New Investigator Awardee Alumnae**

12:30 pm – 2:30 pm ***Poster Session I with Box Lunches***
Royal Palm V-X
****See Pages 71-80 for a complete listing of poster titles and presenters.***

Workshops

2:45 pm – 5:45 pm ***Developing Dynamic, Sequential Treatments that Optimize Mental Health Outcomes: Experiences with Novel Clinical Trial Design***
Grand Ballroom G-H

Chair: Susan A. Murphy, Ph.D., University of Michigan
Co-Chair: Daniel Almirall, Ph.D., University of Michigan

2:45 pm – 3:10 pm **Developing Dynamic, Sequential Treatments that Optimize Mental Health Outcomes: Introduction to Adaptive Interventions and SMART Study Design Principles**
Susan A. Murphy, Ph.D., University of Michigan and Daniel Almirall, Ph.D., University of Michigan

3:10 pm – 3:15 pm **Discussion**

3:15 pm – 3:40 pm **SMART Studies for Alcohol and Cocaine Dependence**
James McKay, Ph.D., University of Pennsylvania Medicine

3:40 pm – 3:45 pm **Discussion**

3:45 pm – 4:10 pm **Adaptive Treatments for Children with ADHD**
William E. Pelham, Ph.D., University of Buffalo

4:10 pm – 4:15 pm **Discussion**

4:15 pm – 4:30 pm **Break**

4:30 pm – 4:55 pm **Testing Variants of Treatments for Substance Use Disorders During Pregnancy**
Hendree Jones, Ph.D., RTI International

4:55 pm – 5:00 pm **Discussion**

5:00 pm – 5:25 pm **Innovative Communication Intervention for Older Nonverbal Children with Autism**
Connie Kasari, Ph.D., University of California, Los Angeles

5:25 pm – 5:45 pm **Discussion**

2:45 pm – 5:45 pm ***Evidence-Based Evaluation and Treatment of Youth with Maladaptive Aggression***
Grand Ballroom I-J

Chair: Christoph U. Correll, M.D., Zucker Hillside Hospital/Albert Einstein College of Medicine*
Co-Chair: Peter S. Jensen, M.D., The Mayo Clinic

2:45 pm – 2:50 pm	**Introduction and Overview**
2:50 pm – 3:05 pm	**Characteristics and Evaluation of Maladaptive Aggression in Youth** Penelope Knapp, M.D., University of California Davis
3:05 pm – 3:20 pm	**Discussion**
3:20 pm – 3:35 pm	**Use of Antipsychotic Medications among Privately and Publicly Insured Youth: Implications for Management of Maladaptive Aggression** Steven Crystal, Ph.D., Rutgers University
3:35 pm – 3:50 pm	**Discussion**
3:50 pm – 4:05 pm	**Randomized Controlled Trial-Based Treatment Guidelines for Psychosocial Interventions in Youth with Maladaptive Aggression** Elizabeth Papadopulos, Ph.D., Pfizer, Inc.
4:05 pm – 4:15 pm	**Discussion**
4:15 pm – 4:30 pm	**Break**
4:30 pm – 4:45 pm	**Systematic Review of Randomized Controlled Trials of Pharmacologic Treatments for Youth with Maladaptive Aggression** Christoph U. Correll, M.D., Zucker Hillside Hospital/ Albert Einstein College of Medicine*
4:45 pm – 5:00 pm	**Discussion**
5:00 pm – 5:30 pm	**Treatment of Aggression: The FDA Perspective** Tiffany Farchione, M.D., Food and Drug Administration*
5:30 pm – 5:45 pm	**Discussion**

***NCDEU New Investigator Awardee Alumnae**

2:45 pm – 5:45 pm ***The Risks and Benefits of Including Suicidal Patients in Clinical Trials: Scientific, Ethical, and Regulatory Perspectives***
Royal Palm Salon II-IV

Chair: Kelly L. Posner, Ph.D., Columbia University, New York State Psychiatric Institute

2:45 pm – 2:55 pm **Introduction**
Kelly L. Posner, Ph.D., Columbia University, New York State Psychiatric Institute

2:55 pm – 3:40 pm **The Case for Inclusion of Suicidal Patients In Trials: Rationale and Strategies**
Barbara Stanley, Ph.D., Columbia University, New York State Psychiatric Institute

3:40 pm – 4:25 pm **A FDA Perspective on Suicidality as a Target for Psychiatric Drug Development**
Mitchell Mathis, M.D., Food and Drug Administration

4:25 pm – 4:35 pm **Break**

4:35 pm – 5:20 pm **Risk Aversion has a Cost: Innovative Solutions for Safety Monitoring and Management**
Increased Precision and Safety with Decreased Burden
Kelly Posner, Ph.D., Columbia University, New York State Psychiatric Institute

5:20 pm – 5:45 pm **General Discussion**

2:45 pm – 5:45 pm ***The Automation of Cognitive Testing in Clinical Trials***
Addison Ballroom

Chairs: Keith A. Wesnes, Ph.D., United BioSource Corporation
Amy Veroff, Ph.D., i3

2:45 pm – 2:55 pm **Welcome & Introduction**

2:55 pm – 3:20 pm **Strategies and Methods to Produce a Stable Neurocognitive Baseline at Randomization: Perspectives from CNS Vital Signs**
Martin Rohling, Ph.D., Department of Psychology, University of South Alabama

3:20 pm – 3:45 pm **The CANTAB System**
Andrew Blackwell, Ph.D., Cambridge Cognition

3:45 pm – 4:10 pm **The CogState System**
Paul Maruff, Ph.D., CogState, Melbourne, Australia

4:10 pm – 4:30 pm **Break**

4:30 pm – 4:55 pm **Automated Tests Capture Aspects of Function Which cannot be Assessed by Traditional Techniques: Examples from The CDR System**
Keith Wesnes, Ph.D. United BioSource Corporation

4:55 pm – 5:20 pm **A Comparison of the ADAS-Cog and the Computerized Neuropsychological Test Battery: Cognitive Domains, Rater Errors, Sample Size Estimates and Power**
Amy Veroff, Ph.D., i3/ Medical and Scientific Affairs

5:20 pm – 5:45 pm **General Discussion**

6:00 pm – 7:30 pm ***NCDEU Reception***
Garden Pool

Notes

AT-A-GLANCE

Wednesday, June 15th

6:45 am – 8:00 am **13th Annual NCDEU Fun Run/Walk**
Meet Outside Golf Pro Shop

7:00 am – 8:30 am **NCDEU Steering Committee Meeting**
Estate Salon I

7:30 am – 8:30 am **ASCP Maintenance of Certification Meeting**
Royal Palm Salon I

7:30 am – 8:30 am **New Investigator Awardee Roundtable Breakfast (Invitation Only)**
Veranda Salon IV

7:30 am – 9:00 am **Continental Breakfast**
Grand & Royal Palm Assemblies (Mizner Center)

8:30 am – 11:00 am **Plenary – *Economics of Drug Development***
Grand Ballroom A-E

11:00 am – 11:15 am **Coffee Break**
Grand/Royal Palm Assemblies (Mizner Center)

11:15 am – 12:45 pm **Concurrent Panel Sessions / Pharma Pipeline Presentations**

Pre-Clinical and Clinical Glutamate Research in Bipolar Disorder: Bipolar Disorder Career Development Institute (CDI) New Investigator Panel Location: Grand Ballroom G-H	**Molecular Targets for Antidepressant Augmentation in Resistant Depression** Location: Grand Ballroom I-J	**Pharmaceutical Pipeline Presentations** Location: Royal Palm II-IV

12:45 pm – 2:45 pm **Poster Session II with Box Lunches**
Royal Palm Salons V-X

3:00 pm – 6:00 pm **Concurrent Workshops**

ISCTM Supported Workshop on Developing Medications for Personalized Medicine: Facing the Challenges of Biomarkers Location: Grand Ballroom G-H	**Underutilization of Evidence-Based Treatment and Monitoring Strategies in Schizophrenia** Location: Grand Ballroom I-J	**Novel Approaches to the Manipulation of the Placebo Response** Location: Royal Palm Salon II-IV	**Do Psychotropics Increase Suicide: Methodological Innovations for Making Sense of Conflicting Evidence** Location: Addison Ballroom

4:30 pm – 4:45 pm **Break During Workshops**

6:45 am – 8:00 am	***13th Annual NCDEU Fun Run/Walk*** ***Meet Outside Golf Pro Shop***
7:00 am – 8:30 am	***NCDEU Steering Committee Meeting*** ***Estate Salon I***
7:30 am – 8:30 am	***ASCP Maintenance of Certification Meeting*** ***Royal Palm Salon I***
7:30 am – 8:30 am	***New Investigator Awardee Roundtable Breakfast (Invitation Only)*** ***Veranda Salon IV***
7:30 am – 9:00 am	***Continental Breakfast*** ***Grand/Royal Palm Assemblies (Mizner Center)***

Plenary Session

8:30 am – 11:00 am	***Plenary – Economics of Drug Development*** ***Grand Ballroom A-E***

Chair: John Kane, M.D., The Zucker Hillside Hospital
ASCP President, 2011

This session will begin with Dr. Ernst R. Berndt of MIT who will discuss the economic model of drug development from the perspective of a business school professor who follows the industry. Drs. Karl Broich of BfArM and Thomas Kaiser of IQWiG will discuss the benefit risk, efficacy and added value of the new legislation in Germany. Drs. Broich and Kaiser will outline their initial experience, type of interaction, and coordinated scientific advice to applicants. Examples such as ASS/Dipyrimadol or antidepressants will be presented, importance of comparators etc. Dr. Joseph Parks, the Medical Director of the Missouri Office of Mental Health, will discuss the decisions that payers (particularly public sector) have to make in establishing formulary/reimbursement policy. Finally, Dr. Husseini Manji of J&J will present an industry perspective on the risk and reward of CNS drug development.

8:30 am – 8:50 am	**Economic Considerations in Psychopharmaceutical Drug Development** Ernst R. Berndt, Ph.D., MIT Sloan
8:50 am – 9:00 am	**Q&A**

8:30 am – 11:00 am (continued)	*Plenary – Economics of Drug Development Grand Ballroom A-E*
9:00 am – 9:20 am	**Benefit Risk, Efficacy and Added Value: The New Legislation in Germany: What is Needed for Drug Approval?** Karl Broich, M.D., Federal Institute of Drugs and Medical Devices (BfArM), Bonn, Germany
9:20 am – 9:30 am	**Q&A**
9:30 am – 9:50 am	**Benefit Risk, Efficacy and Added Value: The New Legislation in Germany: What is Needed for Added Value?** Dr. med. Thomas Kaiser, Ressortleiter Arzneimittelbewertung, Institut für Qualität and Wirtschaftlichkeit in Gesundheitswesen (IQWiG)
9:50 am – 10:00 am	**Q&A**
10:00 am – 10:20 am	**Payers Decisions in Establishing Formulary/ Reimbursement Policy** Joseph Parks, M.D., Medical Director of the Missouri Office of Mental Health
10:20 am – 10:30 am	**Q&A**
10:30 am – 10:50 am	**The Risks and Rewards of CNS Drug Development for the Pharmaceutical Industry** Husseini Manji, M.D., Johnson & Johnson Pharmaceuticals
10:50 am – 11:00 am	**Q&A**
11:00 am – 11:15 am	***Coffee Break*** ***Grand/Royal Palm Assemblies (Mizner Center)***

Panel Sessions / Pharma Pipeline Presentations

11:15 am – 12:45 pm ***Pre-Clinical and Clinical Glutamate Research in Bipolar Disorder: 'Bipolar Disorder Career Development Institute (CDI) New Investigator Panel Grand Ballroom G-H***

Chair: Joseph R. Calabrese, M.D., Case Western Reserve University, University Hospitals Case Medical Center
Co-Chair: Bryan K. Tolliver, M.D., Ph.D., Medical University of South Carolina

11:15 am – 11:35 am **Glutamate Neurotransmission as a Potential Therapeutic Target in Bipolar Disorder: Overview of Evidence and Implications for Treatment of Co-Occurring Disorders**
Bryan K. Tolliver, M.D., Ph.D., Medical University of South Carolina

11:35 am – 11:55 am **Brain Glutamatergic Characteristics of Pediatric Offspring of Parents with Bipolar Disorder**
Manpreet Singh, M.D., Stanford University School of Medicine*

11:55 am – 12:15 pm **Abnormal Glutamatergic Neurotransmission and Neuronal- Glial Interactions in Acute Mania**
Dost Ongur, M.D., Ph.D., McLean Hospital/Harvard Medical School

12:15 pm – 12:45 pm **Discussion**
Mary Phillips, M.D., University of Pittsburgh School of Medicine

11:15 am – 12:45 pm ***Molecular Targets for Antidepressant Augmentation in Resistant Depression Grand Ballroom I-J***

Chair: Madhukar H. Trivedi, M.D., University of Texas Southwestern Medical Center

11:15 am – 11:17 am **Welcome and Introduction**
Madhukar H. Trivedi, M.D., University of Texas Southwestern Medical Center

***NCDEU New Investigator Awardee Alumnae**

11:15 am – 12:45 pm (continued)	***Molecular Targets for Antidepressant Augmentation in Resistant Depression Grand Ballroom I-J***
11:17 am – 11:37 am	**The Dopamine Transporter as a Target in Resistant Depression** Madhukar H. Trivedi, M.D., University of Texas Southwestern Medical Center
11:37 am – 11:55 am	**Agonists and Antagonists of Serotonin and Norepinephrine Receptors. Using Deductive Logic to Identify Molecular Targets for Augmentation Strategies in MDD** George Papakostas, M.D., Massachusetts General Hospital (MGH)*
11:55 am – 12:13 pm	**The Role of Nicotinic Receptors in the Development of Augmentation Strategies** Leslie Jacobson, M.D., Pfizer
12:13 pm – 12:30 pm	**Therapeutic Effects of Methylation and One-Carbon Cycle Compounds in MDD and their Augmentation Properties** Maurizio Fava, M.D., Massachusetts General Hospital (MGH)
12:30 pm – 12:45 pm	**Panel Discussion**
11:15 am – 12:45 pm	***Pharmaceutical Pipeline Presentations Royal Palm II-IV***

Chair: Carlos Zarate, M.D., National Institute of Mental Health
NCDEU 2011 Program Chair*

11:15 am – 11:25 am	**The Alpha7 Neuronal Nicotinic Receptor (NNR) Agonist TC-5619 had Beneficial Effects and was generally Well Tolerated in a Phase 2 Trial in Cognitive Dysfunction in Schizophrenia (CDS)** Geoffrey Dunbar, M.D., Targacept, Inc.
11:25 pm – 11:35 pm	**SRX246: A Novel Vasopressin 1a Antagonist for Stress-related Disorders** Neal Simon, Ph.D., Azevan Phamaceuticals, Inc.

***NCDEU New Investigator Awardee Alumnae**

11:15 am – 12:45 pm (continued)	***Pharmaceutical Pipeline Presentations Royal Palm II-IV***
11:35 am – 11:45 am	**The PNB01 Clinical Development Program: A Novel Boosting Antidepressant Therapy** Erik Buntinx, M.D., PharmaNeuroBoost NV
11:45 am – 11:55 am	**Augmentation with OPC-34712, a Novel Psychotropic, Improves Self-Reported Depressive Symptoms in Patients Treated for Major Depressive Disorder** Aleksandar Skuban, M.D., Otsuka America Pharmaceutical, Inc.
11:55 am – 12:05 pm	**Reduction in HPA Axis Activation after Acute Psychosocial Stress by CXB722 in Healthy Volunteers** Daniel Burch, M.D., CeNeRx BioPharma
12:05 pm – 12:15 pm	**Early Clinical Development of the Amyloid Anti-Aggregation Agent (ELND005) as a Potential Treatment of Alzheimer's Disease (AD)** Susan Abushakra, M.D., Elan Pharmaceuticals, Inc.
12:15 pm – 12:25 pm	**Biomarkers of Neuronal and Glial Homeostasis** Andreas Jeromin, Ph.D., Banyan Biomarkers, Inc.
12:25 pm – 12:35 pm	**Use of CSF Biomarkers to Guide Clinical Drug Development of a Gamma Secretase Inhibitor ELND006 in Alzheimer's Disease** Eliseo Salinas, M.D., Elan Pharmaceuticals, Inc.
12:35 pm – 12:45 pm	**Evaluation of a Unique Nanogram-Dose Intranasal Aerosol for the Acute Management of Social Anxiety Disorder Symptoms** Michael Liebowitz, M.D., Columbia University
12:45 pm – 12:55 pm	**Update On Recent Neuropsychiatric Therapeutics Research** David Michelson, M.D., Merck
12:45 pm – 2:45 pm	***Poster Session II with Box Lunches*** ***Royal Palm Salons V-X*** ****See Pages 81-89 for a complete listing of poster titles and presenters.***

Workshops

3:00 pm – 6:00 pm ***ISCTM Supported Workshop on Developing Medications for Personalized Medicine: Facing the Challenges of Biomarkers Grand Ballroom G-H***

Chair: Larry Alphs, M.D., Ph.D., Ortho-McNeil Janssen

3:00 pm – 3:15 pm	**Overview and Objectives** Larry Alphs, M.D., Ph.D., Ortho-McNeil Janssen
3:15 pm – 3:35 pm	**Biomarkers as Tools for Early Drug Development: NIMH Perspective** Robert Heinssen, Ph.D., National Institute of Mental Health
3:35 pm – 3:45 pm	**Statistical, Regulatory, Industry Response** Panel Discussion
3:45 pm – 3:55 pm	**Open Discussion**
3:55 pm – 4:15 pm	**Development of Predictive Biomarkers in CNS: Methodological Challenges** George Garibaldi, M.D., Roche
4:15 pm – 4:25 pm	**Academic, Regulatory, Statistical Response** Panel Discussion
4:25 pm – 4:30 pm	**Open Discussion**
4:30 pm – 4:45 pm	**Break**
4:45 pm – 5:00 pm	**Biomarkers as Tools for Drug Development: Statistical Challenges** Andrew Leon, Ph.D., Cornell Medical Center*
5:00 pm – 5:10 pm	**Academic, Regulatory, Industry Response** Panel Discussion
5:10 pm – 5:15 pm	**Open Discussion**

***NCDEU New Investigator Awardee Alumni**

3:00 pm – 6:00 pm (continued)	***ISCTM Supported Workshop on Developing Medications for Personalized Medicine: Facing the Challenges of Biomarkers Grand Ballroom G-H***
5:15 pm – 5:30 pm	**Biomarkers as Tools for Drug Approval: Regulatory Perspective on Efficacy And Safety Issues** Ni Khin, M.D., Food & Drug Administration
5:30 pm – 5:45 pm	**Biomarkers as Tools for Drug Approval: Regulatory Perspective on Efficacy and Safety Issues** Karl Broich, M.D., Federal Institute of Drugs and Medical Devices, Bonn, Germany
5:45 pm – 5:55 pm	**Academic, Statistical, Industry Response** Panel Discussion
5:55 pm – 6:00 pm	**Open Discussion**
3:00 pm – 6:00 pm	***Underutilization of Evidence-Based Treatment and Monitoring Strategies in Schizophrenia Grand Ballroom I-J***

Chair: John Kane, M.D., The Zucker Hillside Hospital
Co-Chair: Christoph Correll, M.D., The Zucker Hillside Hospital*

3:00 pm – 3:10 pm	**Welcome and Introduction** John Kane, M.D., The Zucker Hillside Hospital
3:10 pm – 3:40 pm	**The Role of Clinician, Patient and Shared Decision-Making in the Application of Evidence-Based Treatment and Monitoring** Stephan Heres, M.D., Technischen Universitaet Muenchen
3:40 pm – 3:50 pm	**Discussion**
3:50 pm – 4:20 pm	**Long-Acting Injectable Antipsychotic Medications in the Community Treatment of Schizophrenia** Mark Olfson, M.D., Columbia University College of Physicians and Surgeons
4:20 pm – 4:30 pm	**Discussion**

***NCDEU New Investigator Awardee Alumni**

3:00 pm – 6:00 pm (continued)	***Underutilization of Evidence-Based Treatment and Monitoring Strategies in Schizophrenia Grand Ballroom I-J***
4:30 pm – 4:45 pm	**Break**
4:45 pm – 5:10 pm	**Underutilization of Clozapine** John M. Kane, M.D., The Zucker Hillside Hospital
5:10 pm – 5:20 pm	**Discussion**
5:20 pm – 5:45 pm	**Inadequate Adherence to Monitoring Guidelines for Cardiometabolic Monitoring of Antipsychotics** Christoph Correll, M.D., The Zucker Hillside Hospital*
5:45 pm – 6:00 pm	**Discussion** Philip S. Wang, M.D., Dr. PH, National Institute of Mental Health
3:00 pm – 6:00 pm	***Novel Approaches to the Manipulation of the Placebo Response Royal Palm II-IV***

Chair: Maurizio Fava, M.D., Massachusetts General Hospital

3:00 pm – 3:05 pm	**Welcome and Introduction** Maurizio Fava, M.D., Massachusetts General Hospital
3:05 pm – 3:35 pm	**The Use of Biomarkers to Refine Subject Enrollment in CNS Clinical Trials** Ian Cook, M.D., University of California, Los Angeles*
3:35 pm – 3:45 pm	**Q&A**
3:45 pm – 4:15 pm	**Relevance of Recruitment Centers' Placebo Response for the Outcome of Multicentric Randomized Clinical Trials in Early Clinical Discovery** Emilio Merlo-Pich, M.D., GlaxoSmithKline
4:15 pm – 4:25 pm	**Q&A**
4:25 pm – 4:45 pm	**Break**

***NCDEU New Investigator Awardee Alumnae**

3:00 pm – 6:00 pm (continued)	***Novel Approaches to the Manipulation of the Placebo Response*** ***Royal Palm Salon II-IV***
4:45 pm – 5:10 pm	**Reducing the Placebo Response with the Sequential Parallel Comparison Design** Roy Tamura, Ph.D. – Eli Lilly & Company
5:10 pm – 5:15 pm	**Q&A**
5:15 pm – 5:40 pm	**Administering Placebo Effects in a Manner Analogous to Dose Escalation** Ted Kaptchuk, OMD – Harvard Medical School
5:40 pm – 5:45 pm	**Q&A**
5:45 pm – 6:00 pm	**Discussion** Maurizio Fava, M.D. – Massachusetts General Hospital
3:00 pm – 6:00 pm	***Do Psychotropics Increase Suicide: Methodological Innovations for Making Sense of Conflicting Evidence*** ***Addison Ballroom***

Chair: Sue M. Marcus, Ph.D., Columbia University New York State Psychiatric Institute; University of Chicago Center for Health Statistics

3:00 pm – 3:25 pm	**Adverse Effects of Antidepressants in Pediatric Anxiety Disorders** Jeffrey A. Bridge, Ph.D., The Research Institute at Nationwide Children's Hospital and The Ohio State University
3:25 pm – 3:35 pm	**Discussion - Presentation 1** Caleb Alexander, M.D., University of Chicago Medical Center
3:35 pm – 3:45 pm	**General Discussion**

3:00 pm – 6:00 pm (continued)	***Do Psychotropics Increase Suicide: Methodological Innovations for Making Sense of Conflicting Evidence*** ***Addison Ballroom***
3:45 pm – 4:10 pm	**Methods for Detecting Suicidality Outcomes in Observational Comparative Effectiveness and Safety** Heather Orton Anderson, Ph.D., and Robert J. Valuck, Ph.D., R.Ph., University of Colorado, Denver
4:10 pm – 4:20 pm	**Discussion - Presentation 2** Caleb Alexander, M.D., University of Chicago Medical Center
4:20 pm – 4:30 pm	**General Discussion**
4:30 pm – 4:45 pm	**Break**
4:45 pm – 5:10 pm	**The Controversy about Antiepileptic Drugs and Suicide: Addressing Confounding by Indication and Other Biases** Sue M. Marcus, Ph.D., Columbia University New York State Psychiatric Institute; University of Chicago Center for Health Statistics
5:10 pm – 5:20 pm	**Discussion - Presentation 3** Caleb Alexander, M.D., University of Chicago Medical Center
5:20 pm – 5:30 pm	**General Discussion**
5:30 pm – 5:40 pm	**Overall Discussion** Caleb Alexander, M.D., University of Chicago Medical Center
5:40 pm – 6:00 pm	**General Discussion**

AT-A-GLANCE

Thursday, June 16, 2011

7:30 am – 9:00 am **Continental Breakfast**
Grand & Royal Palm Assemblies (Mizner Center)

8:30 am – 10:00 am **Concurrent Panel Sessions**

The Treatment of Early-Age Mania Study (TEAM) Location: Royal Palm Salon I-II	**An Integrated Approach to Biomarker Discovery in Mood Disorders** Location: Royal Palm Salon III-IV	**NIMH Panel - Accelerating Discovery of Preemptive and Personalized Interventions for Mental Disorders: A Report from the National Advisory Mental Health Council** Location: Royal Palm Salon VII-VIII	**NIDA Panel - Non-Substitution Therapies to Treat Substance Use Disorders** Location: Royal Palm Salon IX-X

10:00 am – 10:15 am ***Coffee Break***
Grand/Royal Palm Assemblies (Mizner Center)

10:15 am – 11:45 am **Panel Sessions**

NIAAA Panel - The Alcohol Clinical Trials Initiative (ACTIVE) Group Location: Royal Palm Salon III-IV	**The Evolving Concept of Mixed Depression** Location: Royal Palm Salon VII-VIII	**Genomics of Treatment Response and Side Effects in Severe Mental Illness** Location: Royal Palm Salon IX-X

12:00 pm **Meeting Adjourns**

Notes

7:30 am – 9:00 am ***Continental Breakfast***
Grand/Royal Palm Assemblies (Mizner Center)

Panel Sessions

8:30 am – 10:00 am ***The Treatment of Early-Age Mania Study (TEAM)***
Royal Palm Salon I-II

Chair: Mark A. Riddle, M.D., Johns Hopkins

8:30 am – 8:35 am **Introduction**
Mark A. Riddle, M.D., Johns Hopkins

8:35 am – 8:55 am **TEAM: Design, Methods, and Sample Characteristics**
John T. Walkup, M.D., Weill Cornell Medical College & New York-Presbyterian Hospital

8:55 am – 9:15 am **TEAM: Primary Outcomes**
Karen D. Wagner, M.D., University of Texas Galveston

9:15 am – 9:35 am **TEAM: Searching for Predictors & Moderators of Treatment Effects**
Benedetto Vitiello, M.D., National Institute of Mental Health

9:35 am – 10:00 am **Discussion**
Graham J. Emslie, M.D., University of Texas Southwestern

8:30 am – 10:00 am ***An Integrated Approach to Biomarker Discovery in Mood Disorders***
Royal Palm Salon III-IV

Chair: Sidney H. Kennedy, M.D., FRCP, University Health Network, Canada

8:30 am – 8:35 am **Introduction**
Sidney H. Kennedy, M.D., FRCP, University Health Network, Canada

8:35 am – 8:52 am **Neuroimaging Biomarkers**
Sidney H. Kennedy, M.D., FRCP, University Health Network, Canada

8:30 am – 10:00 am (continued)	***An Integrated Approach to Biomarker Discovery in Mood Disorders*** ***Royal Palm Salon III-IV***
8:52 am – 9:09 am	**Genetic Biomarkers** Allan Young, M.D., Ph.D., FRCPC, University of British Columbia
9:09 am – 9:26 am	**Metabolomic Biomarkers** Roger McIntyre, M.D., FRCPC, University Health Network, Canada
9:26 am – 9:43 am	**Proteomics and Bioinformatics** Kenneth Evans, Ph.D., Ontario Cancer Biomarker Network
9:43 am – 10:00 am	**General Discussion** Robert M. Post, M.D., Bipolar Collaborative Network
8:30 am – 10:00 am	***NIMH Panel - Accelerating Discovery of Preemptive and Personalized Interventions for Mental Disorders: A Report from the National Advisory Mental Health Council*** ***Royal Palm Salon VII-VIII***

Chair: David Sommers, Ph.D., National Institute of Mental Health

8:30 am – 9:00 am	**Workgroup Background, Process, and Recommendations** TBA
9:00 am – 9:30 am	**A Neurodevelopmental Perspective on Intervention Development** LinMarie Sikich**,** M.D., University of North Carolina at Chapel Hill
9:30 am – 10:00 am	**Optimizing NIMH-Supported Clinical Trials Research** Robert Heinssen, Ph.D., National Institute of Mental Health

8:30 am – 10:00 am ***NIDA Panel - Non-Substitution Therapies to Treat Substance Use Disorders***
Royal Palm Salon IX-X

Chair: Phil Skolnick, Ph.D., D.Sc., National Institute of Drug Abuse
Co-Chair: David McCann, Ph.D., National Institute of Drug Abuse

8:30 am – 8:55 am **Glutamate-Based Approaches to Substance Use Disorders**
Lori A. Knackstedt, Ph.D., Medical University of South Carolina

8:55 am – 9:00 am **Discussion**

9:00 am – 9:25 am **The Promise of Selective 5-HT2CR Agonists as Abstinence Enhancers**
Kathryn A. Cunningham, Ph.D., University of Texas Medical Branch

9:25 am – 9:30 am **Discussion**

9:30 am – 9:55 am **Kappa Opioid Antagonists show Therapeutic Potential in Animal Models of Stress-induced Mood Disorders and Drug Addiction Risk**
Charles Chavkin, Ph.D., University of Washington

9:55 am – 10:00 am **Discussion**

10:00 am – 10:15 am ***Coffee Break***
Grand/Royal Palm Assemblies (Mizner Center)

Panel Sessions

10:15 am – 11:45 am ***NIAAA Panel - The Alcohol Clinical Trials Initiative (ACTIVE) Group***
Royal Palm Salon III-IV

Chair: Raymond Anton, M.D., Medical University of South Carolina

10:15 am – 10:25 am **Introduction**
Raymond Anton, M.D., Medical University of South Carolina

10:25 am – 10:40 am **Alcohol Use Disorders as a Target for Clinical Drug Development: Perspective from Industry**
Joseph Palumbo, M.D., Johnson & Johnson Pharmaceutical Research and Development

10:40 am – 10:55 am **Evolution of FDA Approach to Clinical Trials for Alcoholism Treatment Drugs**
Celia Winchell, M.D., Center for Drug Evaluation and Research

10:55 am – 11:10 am **ACTIVE Collaboration: Outcomes Measurement in Alcohol Use Disorders**
Rebecca Robinson, M.S., Global Health Outcomes Lilly Research Labs

11:10 am – 11:25 am **Alcohol Trials: Treatment Endpoints, Grace Periods, Trial Duration, and Placebo Effect**
Raye Z. Litten, Ph.D., National Institute on Alcohol Abuse and Alcoholism

11:25 am – 11:45 am **General Discussion**

10:15 am – 11:45 am ***The Evolving Concept of Mixed Depression***
Royal Palm Salon VII-VIII

Chair: Terence A. Ketter, M.D., Stanford University

10:15 am – 10:20 am **Introduction**
Terence A. Ketter, M.D., Stanford University

10:20 am – 10:35 am **Is Irritable Depression a Form of Mixed Depression? - Lessons from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D)**
Roy Perlis, M.D., M.Sc., Massachusetts General Hospital*

10:35 am – 10:50 am **Mixed Depression in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) and the Stanley Foundation Bipolar Network (SFBN)**
Terence A. Ketter, M.D., Stanford University

10:50 am – 11:05 am **Proposals for Mixed Depression in the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5)**
Ellen Frank, Ph.D., Western Psychiatric Institute

11:05 am – 11:20 am **Potential Therapeutic Implications of Mixed Depression**
Charles L. Bowden, M.D., University of Texas Health Science Center

11:20 am – 11:35 am **Regulatory Implications of Mixed Depression**
Mitchell Mathis, M.D., Food and Drug Administration

11:35 am – 11:45 am **General Discussion**

***NCDEU New Investigator Awardee Alumni**

10:15 am – 11:45 am ***Genomics of Treatment Response and Side Effects in Severe Mental Illness***
Royal Palm Salon IX-X

Chair: Philip Harvey, Ph.D., University of Miami Miller School of Medicine
Co-Chair: Amanda Myers, Ph.D., University of Miami Miller School of Medicine

10:15 am – 10:20 am **Introduction**
Philip Harvey, Ph.D., University of Miami Miller School of Medicine
Amanda Myers, Ph.D., University of Miami Miller School of Medicine

10:20 am – 10:35 am **Genomic Influences on the Quality of Depression as a Response to Early Trauma**
Amanda Myers, Ph.D., University of Miami Miller School of Medicine

10:35 am – 10:50 am **Genomics Influences on Psychotic Symptoms and Treatment Nonresponse in Depression**
Alan Schatzberg, M.D., Stanford University School of Medicine

10:50 am – 11:05 am **Metabolic Syndromes in Schizophrenia: General vs. Specific Genomic Influences**
John Newcomer, M.D., University of Washington School of Medicine

11:05 am – 11:20 am **Disability as a Heritable Phenotype in Severe Mental Illness**
Philip Harvey, Ph.D., University of Miami Miller School of Medicine

11:20 am – 11:30 am **Discussion**
Claes Wahlsted, M.D., Ph.D., The Scripps Research Institute

11:30 am – 11:45 am **General Discussion**

12:00 pm ***Meeting Adjourns***

Tuesday, June 14

12:30 pm – 2:30 pm **Poster Session I**
Royal Palm Salon V-X

1 **A Combined EEG-Behavioral Test of Maintenance of Attention can Differentiate ADHD from Normal Adults**
Bijan Bastani, NorthCoast Clinical Trials
MO Modarress

2 **Extensive Comorbid Personality Disorder Symptoms are Associated with Limited Response to ADHD Treatment**
Fred Reimherr, University of Utah
Erika Williams, Barrie Marchant, John Olsen, Corinne Halls, Reid Robison

3 **Pharmacokinetic Profile of Clonidine Hydrochloride Extended-Release Tablets in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder**
Raul Silva, Academic Behavioral Center, New York

4 **Escitalopram in the Treatment of Non-Depressed Elderly Patients with Generalized Anxiety Disorder**
Olga Brawman-Mintzer, Medical University of South Carolina
Paul Nietert, Kathryn Vankirk, Erin Jones, Marilyn Stuckey, Crystal Flynn Longmire, Jacobo Mintzer

5 **Transient Spikes in Depressive Symptoms over the Course of Psychotherapy and Pharmacotherapy Treatment for Chronic PTSD**
Stephanie Keller, Case Western Reserve University
Norah Feeny, Lori Zoellner


6 **The FGF14:Nav Channel Complex as a New Target of GSK3**
Fernanda Laezza, UTMB
Alexander Shavkunov, Tetyana Buzhdygan


7 **Impact of Increasing Adult Hippocampal Neurogenesis on Cognition and Mood**
Amar Sahay, Columbia University

8 **Understanding of Influence on Placebo Response by Investigators and Site Staff in CNS Clinical Trials**
David Daniel, United BioSource Corporation
Antony Loebel, Josephine Cucchiaro, Jean Dries

 = **New Investigator Awardee**

9 **Executive Functioning of Adolescents with Depression Associated with Bipolar Disorder**
Arman Danielyan, Cincinnati Children's Hospital Medical Center
Jeffrey Welge, Paula Shear, Caleb Adler, Kiki Chang, Melissa DelBello

10 **DSM-5 Mixed Features Specifier may Increase Complexity without Enhancing Milder Mixed Symptom Detection in Bipolar Disorder Patients: A 36 Case Series**
Terence Ketter, Stanford University
Shefali Srivastava, Po Wang

11 **Zonisamide for Bipolar Depression: A Randomized, Double-Blind, Placebo-Controlled, Adjunctive Trial**
Michael Knable, Bethesda Behavioral Sciences
Deborah Daupinais, Norman Rosenthal

12 **Does Shorter vs. Longer Time to Stabilization in Patients with Bipolar I Disorder Predict Relapse Prevention? A Post-Hoc Analysis of an Adjunctive Aripiprazole Clinical Trial (CN138-189)**
Prakash Masand, Duke University Medical Center
Mauricio Tohen, Amy Everitt, Ross Baker, Robert Forbes, Berit Carlson

13 **Relationship of Baseline Metabolic Status to Efficacy Outcomes in Bipolar Disorder Patients: Analysis of Pooled Data from Ziprasidone Monotherapy Clinical Trials**
Elizabeth Pappadopulos, Pfizer Inc.
Roger McIntyre, Francine Mandel

14 **Tolerability Profile of Ziprasidone versus Placebo during Acute Treatment of Schizophrenia, Mania or Bipolar Depression**
Elizabeth Pappadapulos, Pfizer Inc.
Keming Gao, Onur Karayal, Sheela Kolluri, Joseph Calabrese

15 **Resting State Functional Connectivity in Adolescents with Bipolar I Disorder**
Manpreet Singh, Stanford University School of Medicine
Ryan Kelley, Erica Sanders, Tenah Acquaye, Sherrie Li, Meghan Howe, Allan Reiss, Kiki Chang

16 **Lithium for the Reduction of Aggression in Conduct Disordered Outpatients**
Richard Malone, Drexel University College of Medicine
Beeta Verma, Manely Ghaffari, Susan West, Jacqueline Cater

= **New Investigator Awardee**

17 **Assessing Feasibility, Reliability, and Validity of Computer-Automated Interactive SMS Text Messages to Self-Report Depression Symptoms in Children and Adolescents Using the Quick Inventory of Depressive Symptomatology–Adolescent**
James Mundt, Center for Psychological Consultation
Graham Emslie, Tracy Reyes, Taryn Mayes, Krystle Joyner, Jessica King

18 **Primary Endpoint Results from the Metabolic Effects of Antipsychotics in Children (MEAC) Study**
John Newcomer, Washington University School of Medicine
Ginger Nicol, Michael Yingling, Karen Flavin, Julie Schweiger, Martha Hessler, Kenneth Schechtman

19 **Assessing the Reliability of Tanner Staging in CNS Trials: A Cross-Cultural Comparison of European, US, and Indian Raters**
Brian Rothman, ProPhase LLC
Mark Opler, Christoph Correll, Gil Zalsman, Ananda Pandurangi, Eva Kohegyi, Nicole Menlow

20 **The Impact of Back Pain in the CO-MED Trial**
Benji Kurian, University of Texas Southwestern Medical Center
A. John Rush, Stephen Wisniewski, David Morris, James Luther, Robert Howland, Madhukar Trivedi

21 **Baseline Metabolic Comorbidities among Patients Newly Initiating Antipsychotic Therapy: A US Health Claims Database Analysis**
John Newcomer, Washington University School of Medicine
Glenn Phillips, Phillip Sarocco, Andrei Pikalov, Masaaki Ogasa, Cynthia Siu, Antony Loebel

22 **Serum BDNF Concentrations are Associated with Cognitive Performance and Cardiopulmonary Fitness in Subjects with Coronary Artery Disease**
Walter Swardfager, Sunnybrook Health Sciences Centre
Nathan Herrmann, Mahwesh Saleem, Paul Oh, Krista Lanctôt

23 **Reconsidering the Criterion for Excluding Comorbid Substance Use Disorders from Clinical Trials for the Treatment of Depression**
Lori Davis, VA Medical Center

24 **Clinical Practive Informing Drug Development Targets in ASD**
Jessica Hellings, University of Kansas Medical Center
Andrew Thome, Patricia Smith, Muhammad Bhatti

 = **New Investigator Awardee**

25 **The LORS Enabled Dialogue: A Collaborative Intervention to Promote Insight and Recovery in Psychotic Disorders**
Sharon Sousa, University of Massachusetts Dartmouth

26 **Validation of a Global Assessment Measure for Fatigue**
Steven Targum, Clintara LLC
Howard Hassman, Maurizio Fava

27 **Ketamine Effect on Neuronal Remodeling in Treatment Resistant Depression as assessed by Magnetic Resonance Imaging**
Chadi Abdallah, SUNY Downstate Medical Center

28 **Clinical Utility of a Multianalyte Biomarker Panel for Major Depressive Disorder (MDD)**
John Bilello, Ridge Diagnostics
Michael Henry, Perry Renshaw, Richard Shelton, George Papakostas, Bo Pi

29 **Improvement of Clinicians' Assessments of Patients at Inclusion Visits in an MDD Clinical Trial**
Joan Busner, Penn State College of Medicine and United BioSource
Stuart Montgomery, David Daniel, Gary Sachs

30 **Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder Patients with No or Minimal Improvement after Antidepressant Monotherapy (CN138-139, CN138-163, CN138-165)**
Daniel Casey, Oregon Health & Science University
Kimberly Laubmeier, Elizabeth Bellocchio, James Eudicone, Zia Rahman, Robert McQuade, Ross Baker

31 **Prescribing Patterns for Patients with Major Depressive Disorder in the Primary Care Setting: Results from the Clinical Outcomes in Measurement-Based Treatment (COMET) Trial**
Trina Chang, Massachusetts General Hospital and Harvard Medical School
Yonghua Jing, Albert Yeung, Iftekar Kalsekar, Tony Hebden, Robert McQuade, Susan Brenneman, Lee Baer, Jonathan Kurlander, Angela Watkins, Jean Siebenaler, Maurizio Fava

 = **New Investigator Awardee**

32 **Clinical Outcomes in Measurement-based Treatment (COMET) Trial: Effectiveness of Communicating Patient-Reported Outcomes on the PHQ9 to Primary Care Physicians in Treatment of Depression**
Trina Chang, Massachusetts General Hospital and Harvard Medical School
Albert Yeung, Yonghua Jing, Lee Bauer, Iftekar Kalsekar, Tony Hebden, Robert McQuade, Susan Brenneman, Jonathan Kurlander, Angela Watkins, Jean Siebenaler, Maurizio Fava

33 **Regional PET Activation with Trigeminal Nerve Stimulation in Major Depression**
Ian Cook, David Geffen School of Medicine at UCLA
Lara Schrader, Cheri Geist, Daniel Silverman, Patrick Miller, Mary Susselman, Christopher DeGiorgio

34 **Do Early Levels of Serum BDNF Predict Treatment Outcome in Major Depression?**
Ian Cook, UCLA Depression Research & Clinic Program and Laboratory for Brain, Behavior, and Pharmacology
Fernando Gomez-Pinilla, Aimee Hunter, Andrew Leuchter

35 **Defining Remission in Major Depression Disorder: Does Duration Matter?**
Sanjay Dubé, Eli Lilly and Company
Susan Ball, JonDavid Sparks, Thomas Konechnik, Mary Anne Dellva, Peter Classi, Celine Goldberger

36 **Efficacy of Exercise Augmentation of SSRI Treatment in Improving Cognitive Function in Major Depressive Disorder**
Tracy Greer, UT Southwestern
Bruce Grannemann, Matthieu Chansard, Madhukar Trivedi

37 **Pilot RCT of SSRI vs Bupropion on Suicidal Behavior and Ideation in At-Risk Depressed Patients**
Michael Grunebaum, Columbia University
Steven Ellis, Naihua Duan, Ainsley Burke, Maria Oquendo, John Mann

38 **Efficacy of Desvenlafaxine 50 mg Compared with Placebo in Patients with Moderate or Severe Major Depressive Disorder: A Pooled Analysis of 6 Randomized, Placebo-Controlled Studies**
Jeff Musgnung, Pfizer Inc
George Papakostas, Larry Culpepper, Rana Fayyad, Christine Guico-Pabia

 = **New Investigator Awardee**

39 **Creating a New Clinically Relevant Endpoint in the PIPCIT Trial Programme: The ESR (Early and Sustained Antidepressant Response)**
Ludo Haazen, PharmaNeuroBoost NV
Michael Thase, Remi van den Broeck, Erik Buntinx

40 **Augmentation by LDX of Escitalopram but not of Venlafaxine in the Porsolt Behavioral Despair Test in Mice**
David Hackett, Shire Development Inc.
Vincent Castagné

41 **Simultaneous Measurement with Hysteresis Analyses of the Effects of Lisdexamfetamine Dimesylate and d Amphetamine on Striatal Levels of Extracellular Dopamine, Locomotor Activity, and Plasma Drug Concentrations in Freely Moving Rats**
David Heal, RenaSci Consultancy Ltd
Helen Rowley, David Hackett

42 **Outcome of Behavioral Activation Therapy in Medication-Responsive Chronic Depression with Persistent Psychosocial Dysfunction: A Pilot Study**
David Hellerstein, Columbia University
Gregory Erickson, Donna O'Shea, Jonathan Stewart, Patrick McGrath, Deborah Deliyannides, Ronit Kishon, Martin McElhiney, Rengin Isik, Ying Chen

43 **Effects of the Insulin Sensitizer Pioglitazone on Cognitive Functioning in Patients with Major Depressive Disorder and Abdominal Obesity**
David Kemp, Case Western Reserve University
Stephen Ganocy, Karu Jayathilake, Herbert Meltzer, Elizabeth Fein, Sarah Obral, Carla Conroy, Robert Bilder, Joseph Calabrese


44 **Effects of Exercise on Inflammatory Cytokines in Nonremitted Major Depressive Disorder**
Chad Rethorst, University of Texas - Southwestern Medical Center


45 **Treating Major Depressive Disorder by Creating Positive Expectations for the Future: A Pilot Study for the Efficacy of Future Directed Therapy (FDT)**
Jennice Vilhauer, Cedars-Sinai Medical Center
Young Sabrina, Chanel Kealoha, Josefine Borrmann, Waguih IsHak, Mark Rapaport, Narineh Hartoonian, Jim Mirocha

 = **New Investigator Awardee**

46 **Striatal and Anterior Cingulate GABA Deficits as Possible Treatment Targets in Adolescents with Tourette's Disorder: A Proton MR Spectroscopy Study**
Vilma Gabbay, New York University
Barbara Coffey, Xiangling Mao, Dikoma Shungu

47 **New Model Curriculums for Teaching Psychopharmacology to Residents, Medical Students, and Primary Care Prescribers**
Ira Glick, Stanford University
Bruce Lydiard

48 **Serious Problems with how Uncontrolled Studies are Conducted and Followed Up**
Rajnish Mago, Thomas Jefferson University
Alexandra Lane, Rajeev Mahajan

49 **Recent Developments in Improving Signal Detection and Reducing Placebo Response**
Craig Mallinckrodt, Eli Lilly
Roy Tamura, Yoko Tanaka


50 **Citicoline Administration and Improved Attentional Performance with Healthy Adult Women**
Erin McGlade, University of Utah Brain Institute
Allison Locatelli, Toshikazu Kamiya, Masahiko Morita, Koji Morishita, Yoichiro Sugimura, Deborah Yurgelun-Todd

51 **Bayesian Analysis of Weighted-Z tests in Adaptive Trial Design**
Cynthia Siu, Data Power (DP), Inc.
Carla Brambilla, Fabrizio Ruggeri

52 **Innovative Web-Based Technologies for Enhancing Quality Implementation of Evidence-Based Interventions and Fostering Better Treatment Outcomes**
Melissa DeRosier, 3-C Institute for Social Development
Danielle Swick, Chris Hehman

53 **Short-term Treatment of Acute Schizophrenia with Lurasidone vs. Quetiapine XR: Effect on Daytime Sleepiness**
Henry Nasrallah, University of Cincinnati College of Medicine
Andrei Pikalov, Josephine Cucchiaro, Jane Xu, Antony Loebel

 = **New Investigator Awardee**

54 **Using a Computerized Diagnostic Instrument as a Tool for Identifying Best Practices**
Melanie Elliott Wilson, TeleSage, Inc.
Benjamin Brodey, Milo Fryling, David Ayer, Heather Nelms, Jackie Koble, Philip Maier, Scott McConnell, Michael First

55 **Efficacy of Iloperidone in Schizophrenia According to Baseline Symptom Severity: Results From a Pooled Analysis of 4 Phase III Clinical Trials**
Gus Alva, ATP Clinical Research
Marla Hochfeld, Xiangyi Meng

56 **Open-Label Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine: A 2-Year, Randomized Study in Outpatients with Schizophrenia**
Elizabeth Brunner, Lilly Research Laboratories
Holland Detke, Peter Weiden, Pierre-Michel Llorca, Moutaz Choukour, Susan Watson, Haya Ascher-Svanum

57 **Long-Term Safety and Tolerability Of Lurasidone in Schizophrenia or Schizoaffective Disorder: A 12-Month, Double-Blind, Active-Controlled Study**
Leslie Citrome, New York University School of Medicine
Josephine Cucchiaro, Kaushik Sarma, Debra Phillips, Robert Silva, Satoru Tsuchiya, Antony Loebel

58 **What can a 5-factor PANSS Analysis tell us about Iloperidone's Efficacy Profile and Optimal Dose?**
Leslie Citrome, New York University, School of Medicine
Marla Hochfeld, Xiangyi Meng

59 **Long-Term Safety and Tolerability of Lurasidone in Patients with Schizophrenia: Results of a 6-Month, Open-Label Extension Study**
Josephine Cucchiaro, Sunovion Pharmaceuticals Inc.
Stephen Stahl, Doreen Simonelli, Joseph Severs, Andrei Pikalov, Antony Loebel

60 **Metabolic and Body Mass Parameters Observed with JNJ-37822681, a Novel Fast- Dissociating D2 Receptor Antagonist, Versus Olanzapine**
Ella Daly, Johnson and Johnson PRD
Justine Kent, Luc Janssens, John Newcomer, Nancy Van Osselaer, Gitta Husken, Peter De Boer, Luc Tritsmans, Mark Schmidt

 = **New Investigator Awardee**

61 **Early Prediction of Sustained Treatment Response with JNJ-37822681, a Novel, Fast- Dissociating D2 Receptor Antagonist, Compared to Olanzapine in Schizophrenia**
Ella Daly, Janssen Pharmaceutica
Ion-George Anghelescu, Luc Janssens, Justine Kent, Peter de Boer, Nancy van Osselaer, Luc Tritsmans, Luc van Nueten, Mark Schmidt

62 **Global Inter-Rater Reliability, Scale Validity, and Local Perception: PANSS Ratings and Reactions from 4 Countries**
Ashleigh DeFries, ProPhase LLC
Mark Opler, Stacy Liechti, Evgenia Ivanova, Larry Yang, Sean Lane

63 **Factors Associated with the Initiation of Clozapine**
Susan Essock, Columbia University Department of Psychiatry
Jennifer Manuel, Yan Wu, Maria Pangilinan, Scott Stroup

64 **Rates of Remission among Patients with Schizophrenia Treated with Olanzapine Long-Acting Injection**
Peter Feldman, Lilly Research Laboratories
David McDonnell, Holland Detke, Chakib Battioui, Hong Liu-Seifert, Haya Ascher-Svanum

65 **The Management of Antipsychotic Treatment Discontinuation and Interruptions using Model-based Simulations**
Dong-Jing Fu, Ortho-McNeil Janssen Scientific Affairs
John Sheehan, Bart Remmerie, Jennifer Kern Sliwa, Larry Alphs, Mahesh Samtani

66 **Early Stage Analysis of Alternative Interventions in Patients with Schizophrenia after First Psychotic Episode**
Nicolas Furiak, Medical Decision Modeling Inc.
Megha Bansal, Harry Smolen

67 **Risk of Cardiovascular Morbidity and Sudden Death with Risperidone and Paliperidone Treatment: Analysis of 64 Randomized, Double-Blind Trials**
Srihari Gopal, Janssen Research & Development
David Hough, Keith Karcher, Isaac Nuamah, Joseph Palumbo, Jesse Berlin, Alan Baseman, Yimei Xu, Justine Kent

68 **Cognitive Performance in Patients with Acute Schizophrenia Treated with Lurasidone: A Double-Blind, Placebo-Controlled Trial**
Philip Harvey, University of Miami Miller School of Medicine
Andrei Pikalov, Josephine Cucchiaro, Antony Loebel

= **New Investigator Awardee**

69 **The Effect of Eszopiclone on Stages of Sleep: Results from Studies in Adult and Elderly Patients with Primary Insomnia**
Gary Zammit, Clinilabs, Inc
Todd Grinnell, Jacqueline Zummo, Edward Schweizer, Randall Marshall

70 **Effects of Medically-Induced Menopause on Mood and Behavior in Healthy Young Women**
Rivi Ben Dor, NIMH
Veronica Harsh, Paige Fortinsky, David Rubinow, Peter Schmidt

71 **OPEN BOARD**

72 **Headaches Associated with Ovarian Supression**
Julia “Jill” Warnock, University of Oklahoma
David Morris, J. Clark Bundren

 = **New Investigator Awardee**

Wednesday, June 15

12:45 pm – 2:45 pm **Poster Session II**
Royal Palm Salon V-X

1 **Comparison of Efficacy between Buprenorphine and Tarmadol in Detoxification of Opiod (Heroin) Dependent Subjects**
Jatinder Chawla, SUNY Downstate Medical Center
Rakesh Lal, Hemraj Pal, Raka Jain, Nina Schooler

2 **Specific Genetic Variants facilitating Disulfiram Pharmacotherapy for Cocaine Dependence**
Thomas Kosten, Baylor
David Nielsen, Jan Lindsay

3 **Prevalence of Metabolic Syndrome (MS) in Veterans with Alcohol Related Disorders Alone and Alcohol and Marijuana Related Disorders Combined**
Roopa Sethi, Carilion Clinic
Benjamin Griffeth, Anita Kablinger, Lauren Lehman

4 **Predictive Ability of the Treatment Motivation Questionnaire (TMQ) in Substance Abuse Treatment**
Roopa Sethi, Carilion Clinic
Steven Lash, Stephanie Fearer

5 **Real-Time fMRI Neurofeedback Targeting Inhibitory Control Brain Activation Decreases Emotional Reactivity to Smoking Cues in Cigarette Smokers**
Luke Stoeckel, Harvard/MGH
Xiaoqian Chai, Oliver Hinds, Alex Tighe, Alice Coakley, Susan Whitfield-Gabrieli, John Gabrieli, Eden Evins

✱ 6 **Reduction in HPA Axis Activation after Acute Psychosocial Stress by CXB722 in Healthy Volunteers**
Daniel Burch, CeNeRx BioPharma
Manhaz Asgharnejad

✱ 7 **Evaluation of a Unique Nanogram-Dose Intranasal Aerosol for the Acute Management of Social Anxiety Disorder Symptoms**
Michael Liebowitz, Columbia University
Ester Salman, Norman Rosenthal, Humberto Nicolini, Louis Monti

= **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

8 **Low Intensity Focused Ultrasound Pulsation: A Novel Noninvasive Intervention for Diagnosing and Treating Brain Disease**
Alexander Bystritsky, UCLA
William Melega, Seung-Schik Yoo

9 **Does Shorter vs. Longer Stabilization in Patients with Bipolar I Disorder Predict Relapse Prevention? Analysis of Results from an Adjunctive Aripiprazole Clinical Trial (CN138-392)**
Zia Rahman, Bristol-Myers Squibb
Charles Bowden, Mark Frye, Robert Hirschfeld, James Eudicone, Ross Baker, Robert Forbes, Berit Carlson

10 **Customized Adherence Enhancement for Individuals with Bipolar Disorder receiving Atypical Antipsychotic Therapy**
Martha Sajatovic, University Hospitals - Case Medical Center
Jennifer Levin, Weronika Micula-Gondek, Tiffany Williams, Christopher Bialko, Kristin Cassidy, Curtis Tatsuoka

11 **How Does Bipolar Depression Respond to Antidepressant Medication?**
Jessica Stewart, Harvard Longwood Psychiatry Residency Training Program
Jonathan Stewart

12 **Impact of Ethnicity on Efficacy and Safety of Ziprasidone in Patients with Schizophrenia or Bipolar Disorder**
Douglas Vanderburg, Pfizer, Inc.
Charles Bowden, Onur Karayal, Sheela Kolluri

✱ 13 **Early Clinical Development of the Amyloid Anti-Aggregation Agent (ELND005) as a Potential Treatment of Alzheimer's Disease (AD)**
Susan Abushakra, Elan Pharmaceuticals, Inc.
Pierre Tariot, Earvin Liang, Gerald Crans, Eliseo Salinas

14 **EVP-6124, an á-7 Agonist for the Treatment of Cognitive Deficits in Alzheimer's - Synergies with AChEIs**
Chaya Bhuvaneswaran, EnVivo Pharmaceuticals
Gerhard Koenig, Daniel Bertrand, Dana Hilt

15 **Utilization of Antipsychotics in Patients with Diagnosis of Dementia in Veterans Affairs Medical Center**
Mohammad Chowdhury, Carilion Clinic
Roopa Sethi, Mamta Sapra

= **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

16 **The Assessment of Raters in an Alzheimer's Study: Experience in Asia**
Amy Veroff, i3 / Scientific Services and Technology
Joan Shen, Johnna Wu, Qi Shen, Huali Wang

17 **Attention Deficts Play a Major Role in the Profile of Cognitive Dysfunction in Parkinson's Disease**
Keith Wesnes, United BioSource Corporation
David Miller, Liesl Allcock, Martin Eccles, Louise Robinson, Andrea Stutt, David Burn

18 **Does the Presence of an Open-Label Antidepressant Lead-In Period Influence Study Outcome in Clinical Trials Examining Augmentation/Combination Strategies in Treatment Partial/Non-Responders with Major Depressive Disorder?**
Nadia Iovieno, MGH, Department of Psychiatry
George Papakostas

19 **Efficacy and Tolerability of ECT using Ketamine Anesthesia: A Double-Blind Randomized Controlled Pilot Study**
Styliani Kaliora, The Zucker Hillside Hospital
Georgios Petrides

20 **Changes in Suicide Risk Measures and Depressive Symptoms with Low Dose Lithium Combined with Citalopram Compared to Citalopram with Placebo in a Group of Severely Ill Depressed and Suicidal Patients**
Arif Khan, Northwest Clinical Research Center
Shirin Khan, Joy Hobus, James Faucett, Vishaal Mehra, Earl Giller, Richard Rudolph

21 **'Placebo control' in Antidepressant Trials: A Misnomer**
Arif Khan, Northwest Clinical Research Center
James Faucett, Pesach Lichtenberg, Walter Brown

22 **Baseline GABA Level Correlates with Response to Antidepressant Treatment in Women with Depression, Anxiety, and Insomnia**
Tara Lauriat, St. Elizabeth's Medical Center
J. Eric Jensen, Perry Renshaw, Michael Henry

= **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

23 **BDNF Genotype and Response to Pharmacotherapy and Psychotherapy for Depression**
Jessica Levenson, University of Pittsburgh Medical Center
Alison Gilbert, Paola Rucci, Vishwajit Nimgaonkar, David Kupfer, Ellen Frank

24 **The Effects of Desvenlafaxine 50 mg on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Subjects**
Alice Nichols, Pfizer Inc.
Tanya Ramey, Shannon Lubaczewski, Yali Liang, Kyle Matschke, Gabriel Braley

25 **Safety of Selegiline Transdermal System in Clinical Practice: Analysis of Adverse Events from Post-Marketing Exposures**
Ashwin Patkar, Duke University Medical Center
Chi-Un Pae, J. Alexander Bodkin, Kimberly Blanchard Portland, Sunil Mehra, Soumya Prasad, Michael Thase

26 **Reductions in CSF Abeta42 in Cognitively-Intact Elderly with Major Depressive Disorder: Possible Implications for the Pathophysiology and Treatment**
Nunzio Pomara, Nathan S. Kline Institute for Psychiatric Research
Davide Bruno, Jay Nierenberg, John Sidtis, Pankaj Mehta, Henrik Zetterberg, Kaj Blennow

27 **Selegiline Transdermal System (STS) for Anxious Depression: A Post Hoc Analysis of 3 Randomized, Placebo-Controlled, Double-Blind Studies**
Donald Robinson, World Wide Drug Development
Kimberly Blanchard Portland, Sunil Mehra

28 **Fluoxetine Blood Levels and Weekly Drug Use Correlate with Treatment Response in Major Depression with Comorbid Alcoholism**
Ihsan Salloum, University of Miami Miler School of Medicine
Jack Cornelius, Antoine Douaihy, Levent Kirisci

29 **Vasopressin 1A Receptor Antagonists as a Novel Treatment for PTSD: Preclinical & Phase 1 Study**
Neal Simon, Azevan Phamaceuticals, Inc.

 = **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

✱ 30 **Augmentation with OPC-34712, a Novel Psychotropic, Improves Self-Reported Depressive Symptoms in Patients Treated for Major Depressive Disorder**
Aleksandar Skuban, Otsuka America Pharmaceutical, Inc.
Arif Khan, Mary Hobart, Peter Zhang, Ye Yang, Claudette Brewer, Robert McQuade, Robert Forbes

✱ 31 **The PNB01 Clinical Development Program: A Novel Boosting Antidepressant Therapy**
Erik Buntinx, PharmaNeuroBoost NV
Ludo Haazen, Remi van den Broeck, Didier de Chaffoy, Michael Thase

32 **Efficacy and Safety of Desvenlafaxine 25 and 50 mg/d in a Randomized, Placebo-Controlled Study of Depressed Outpatients**
Karen Tourian, Pfizer Inc.
Eunhee Hwang, Linda Mele, Tadashi Umeda, Cecile Vialet

33 **A Randomized, Double-blind, Placebo-Controlled Study of Desvenlafaxine 10 and 50 mg/d Efficacy and Safety in Depressed Outpatients**
Karen Tourian, Pfizer Inc.
Michael Liebowitz, Eunhee Hwang, Linda Mele

34 **Depressed Patients who were Partial or Non-Responders to Citalopram Reached Remission Equally often with Add-On TC-5214, a Neuronal Nicotinic Channel Modulator**
Geoffrey Dunbar, Targacept Inc.
David Hosford, Madhukar Trivedi

35 **Effects of Lisdexamfetamine Dimesylate, a Long-Acting Prodrug Stimulant, on Quality of Life and Fatigue in MDD Patients With Residual Symptoms: Results of a Placebo-controlled Augmentation Trial**
Madhukar Trivedi, Univ. Texas Southwestern
Andrew Cutler, Cynthia Richards, Robert Lasser, Brooke Geibel, Joseph Gao, Angelo Sambunaris, Ashwin Patkar

36 **Sustained Remission, Number Needed to Treat, and Complete Remission in a Placebo-Controlled Levomilnacipran Study in Major Depressive Disorder**
Peter Werner, Forest Research Institute
Jennifer Li, Lucilla Mansuy, Anjana Bose

 = **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

37 **A Randomized, Double-Blind, Placebo-Controlled, Pooled Data Single-Site Assessment of the Efficacy and Safety of Vilazodone in Patients with Major Depressive Disorder**
Charles Wilcox, Pharmacology Research Institute
Nader Oskooilar, Barbara Katz, Daniel Grosz, My-Linh Tong, Judy Morrissey, Mellissa Henry, Don De Francisco

38 **Psychometric Properties of Chinese Translations of the Quick Inventory of Depressive Symptomatology, Self Report**
Albert Yeung, MGH Depression Clinical and Research Program
Gregory Feldman, Paola Pedrelli, Katherine Hails, Maurizio Fava, Tracy Reyes, James Mundt

39 **An Open-Label Trial of Dronabinol, a Cannabinoid Agonist, in the Treatment of Trichotillomania**
Jon Grant, University of Minnesota
Brian Odlaug

40 **Gender Differences in a Placebo-Controlled Trial of Fluoxetine for Body Dysmorphic Disorder**
Katharine Phillips, Rhode Island Hospital/Alpert Medical School of Brown University
Megan Kelly

41 **Clinical Predictors of Weight Change during Long-Term Risperidone Treatment**
Chadi Calarge, The University of Iowa
Diqiong Xie, Miriam Zimmerman

42 **A Comparison Between Risperidone and Paliperidone: Are These Two Different Drugs?**
Maria Corena-McLeod, Mayo Clinic Jacksonville
Natalia Gorron, Elliott Richelson

43 **An Open Label Trial of Arbaclofen in Autism Spectrum Disorder Shows Improvements in Multiple Symptom Domains**
Jeremy Veenstra-VanderWeele, Vanderbilt University
Bryan King, Craig Erickson, Lawrence Ginsberg, Raun Melmed, Lawrence Scahill, Linmarie Sikich, James McCracken, Barbara Rathmell, Randall Carpenter, Mark Bear, Paul Wang

= **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

44 **Relationship between the Clinical Global Impression of Severity for Schizoaffective Disorder Scale and Established Mood Scales for Mania and Depression**
Dong-Jing Fu, Ortho-McNeil Janssen Scientific Affairs, LLC
Ibrahim Turkoz, Cynthia Bossie, John Sheehan, Larry Alphs

45 **15 Years of Research on Transition Rates to Psychosis: How Prodromal are our Putatively Prodromal Patients?**
Marta Hauser, The Zucker Hillside Hospital, North Shore Long Island Jewish Medical Center

46 **Retrospective Comparison of Medical Advance Directive Inquiry and Documentation for In-Patients in Psychiatry, Surgery and Internal Medicine in Salem Veterans Affairs Medical Center (SVAMC)**
Echezona Anunobi, Carilion Clinic
Mark Detweiler, Roopa Sethi, Reena Thomas

47 **I Was Blind, But Now I See: A Site's Perspective and Lessons Learned**
Patricia Brown, CNS Healthcare
Melissa Ball, Brian Hunter

48 **The Importance of Rigor in Post-Baseline Assessments in CNS Clinical Trials**
Michael Detke, MedAvante
Janet Williams, Kenneth Kobak

49 **Variation in MADRS Reliability Over the Course of Randomized Controlled Trials: Comparison of Computer vs Site-Based Rater Administration**
Gary Sachs, Mass General & United BioSource Corporation
Suzanne Edman, Daniel DeBonis

50 **Predictors of Response and Sustained Response With Iloperidone: Results from 2 Phase III Studies**
Richard Jackson, Wayne State University
Greg Mattingly, Marla Hochfeld, Xiangyi Meng

51 **A Meta-Analysis of Pharmacodynamic Testing with the NeuroCart used in the Early Phase Drug Development of CNS Depressant Agents**
Joop van Gerven, Centre for Human Drug Research
Justin Hay

= **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

✱ 52 **The Alpha7 Neuronal Nicotinic Receptor (NNR) Agonist TC-5619 had Beneficial Effects and was Generally Well Tolerated in a Phase 2 Trial in Cognitive Dysfunction in Schizophrenia (CDS)**
Geoffrey Dunbar, Targacept Inc.
Jeffrey Lieberman, Anthony Segreti, David Hosford

53 **The Virtual Reality Functional Capacity Assessment Tool (VRFCAT): A New Co-Primary Cognitive Measure for Schizophrenia Drug Trials**
Richard Keefe, Duke University Medical Center
Kolleen Fox, Stacy Ruse, Vicki Davis, Ricardo Pietrobon, Philip Harvey, Ranga Krishnan

54 **eSNP Association Analysis across Different Brain Regions for Prioritization of Schizophrenia Candidate Genes from Previous Genetic Association Studies for Therapeutic Targets**
Sanghyeon Kim, SMRI
Maree Webster

55 **Response to Atypical Antipsychotic Therapy among Patients with Predominant Versus Prominent Negative Symptoms**
Bruce Kinon, Lilly Research Laboratories
Virginia Stauffer, Guochen Song, Haya Ascher-Svanum, Lei Chen, Peter Feldman, Robert Conley

56 **Serotonin 6 Receptor Gene and Schizophrenia: Case-Control Study, Meta-Analysis and Endophenotype-Related Traits of Cognitive Function and Acoustic Startle Response**
Taro Kishi, The Zucker Hillside Hospital
Yasuhisa Fukuo, Tomo Okochi, Toshiya Inada, Norio Ozaki, Christoph Correll, Nakao Iwata

57 **Nicotine Addiction, Endophenotype-Related Traits (Cognitive Function and Prepulse Inhibition) of Schizophrenia, and Neuronal Nicotinic Acetylcholine Receptor Genes (CHRNA4 and CHRNB2)**
Taro Kishi, The Zucker Hillside Hospital
Yasuhisa Fukuo, Tomo Okochi, Christoph Correll, Nakao Iwata

58 **Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second Generation Antipsychotics versus First Generation Antipsychotics**
Taishiro Kishimoto, The Zucker Hillside Hospital
Vishesh Agarwal, Allyssa Brody, Taro Kishi, Gennady Gelman, John Kane, Christoph Correll

= **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

59 **Improving the Value of Care for Individuals with Serious Mental Illness through Implementation and Evaluation of CommonGround**
Jane Kogan, Community Care Behavioral Health Organization
Bradley Stein, Mark Mihalyo, Mark Sorbero, James Schuster

60 **Insight and its Association with Baseline Characteristics of People with Schizophrenia Randomized to Long Acting Injectable Risperidone or Oral Atypical Antipsychotics**
Maju Koola, Maryland Psychiatric Research Center, University of Maryland
Juan Bustillo, John Lauriello, Nina Schooler

61 **Prior Trial Experience and Stipend Amount not associated with Improvement on Placebo in Antipsychotic Randomized Controlled Trials for Schizophrenia**
Robert Litman, CBH Health, LLC
Jelena Saillard, Susan Szymialis

62 **Lurasidone in the Treatment of Acute Schizophrenia: Results of the Double-Blind, Placebo-Controlled, 6-Week, Pearl 3 Trial**
Josephine Cucchiaro, Sunovion Pharmaceuticals Inc.
Antony Loebel, Kaushik Sarma, Jane Xu, Jay Hsu, Amir Kalali, Steven Potkin

63 **OPEN BOARD**

64 **Comparative Effectiveness of Risperidone Long-Acting Injection vs. Conventional Depot Injections in Schizophrenia**
Jimmi Nielsen, Aalborg Psychiatric Hospital
Signe Jensen, Rasmus Friis, Christoph Correll

65 **A Post-Hoc Comparison of Paliperidone Palmitate to Oral Risperidone at Initiation of Risperdal CONSTA in Acutely Symptomatic Schizophrenia**
Gahan Pandina, Johnson & Johnson Pharmaceutical Research & Development
David Hough, Rosanne Lane, Isaac Nuamah, Bart Remmerie, Danielle Coppola, Srihari Gopal

= **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

66 **Effect of Lurasidone on Weight and Metabolic Parameters: Results from Pooled Short-Term Placebo-Controlled and Long-Term Trials in Schizophrenia**
Andrei Pikalov, Sunovion Pharmaceuticals Inc.
Josephine Cucchiaro, Masaaki Ogasa, Robert Silva, Jay Hsu, Jane Xu, Antony Loebel

67 **Use of Audio-Digital Recordings for External Monitoring to Improve Subject Selection in a Schizophrenia Trial**
Mark Rapaport, Cedars-Sinai Medical Center
Jessica Little, Larry Ereshefsky, Nicholas Demartinis, Steven Targum

68 **Study Quality and Placebo Response in Randomized Controlled Trials in Schizophrenia Conducted 1966-2009**
Cynthia Siu, Data Power (DP), Inc.
Ofer Agid, Steven Potkin, Krysta McDonald, Gary Remington

69 **A Phase 1b Study of the Tolerability and Safety of LY2140023 Monohydrate when added to Atypical Antipsychotics in Subjects with Schizophrenia or Schizoaffective Disorder**
Virginia Stauffer, Eli Lilly and Company
Mosun Ayan-Oshodi, Eshetu Wondmagegnehu, Rebecca Wrishko, Ludmila Kryzhanovskaya, Shelby Anderson

70 **Comparing Measures of Negative Symptoms of Schizophrenia in Clinical Trials: The Investigators' View**
Dawn Velligan, UTHSCSA
David Daniel, Nicholas Greco IV, John Bartko

71 **The Many Faces of Akathisia Revisited: Akathisia Signal from Controlled Clinical Trials**
Peter Weiden, Center for Cognitive Medicine
Leslie Citrome, John Davis, Marla Hochfeld, Xiangyi Meng

= **New Investigator Awardee** ✱ **Pharma Pipeline Presentation**

Index

Abdallah, Chadi 26, 74
Abushakra, Susan 57, 82
Acquaye, Tenah 72
Acri, Jane B. 30
Adler, Caleb 72
Agarwal, Vishesh 88
Agid, Ofer 90
Alexander, Caleb 61, 62
Allcock, Liesl 83
Almirall, Daniel 46
Alphs, Larry 58, 79, 87
Alva, Gus 78
Anderson, Heather Orton 62
Anderson, Shelby 90
Anghelescu, Ion-George 79
Anton, Raymond 68
Anunobi, Echezona 87
Ascher-Svanum, Haya 78, 79, 88
Asgharnejad, Manhaz 81
Ayan-Oshodi, Mosun 90
Ayer, David 78
Baer, Lee 74
Baker, Ross 72, 74, 82
Ball, Melissa 87
Ball, Susan 75
Bansal, Megha 79
Barch, Deanna 36
Bartko, John 90
Baseman, Alan 79
Bassan, Merav 30
Bastani, Bijan 71
Battioui, Chakib 79
Bauer, Lee 75
Bear, Mark 86
Beebe, Katherine 33
Bellocchio, Elizabeth 74
Ben Dor, Rivi 26, 80
Berlin, Jesse 79
Berndt, Ernst R. 53
Bertrand, Daniel 82
Bhatti, Muhammad 73
Bhuvaneswaran, Chaya 82
Bialko, Christopher 82
Bilder, Robert 76
Bilello, John 74
Blackwell, Andrew 49
Blennow, Kaj 84
Bodkin, J. Alexander 84
Borrmann, Josefine 76
Bose, Anjana 85
Bossie, Cynthia 87
Bowden, Charles L. 69, 82
Braley, Gabriel 84
Brambilla, Carla 77
Brawman-Mintzer, Olga 71
Brenneman, Susan 74, 75
Brewer, Claudette 85
Bridge, Jeffrey A. 61
Brodey, Benjamin 78
Brody, Allyssa 88
Broich, Karl 32, 34, 53, 54, 59
Brown, Patricia 87
Brown, Walter 83
Brunner, Elizabeth 78
Bruno, Davide 84
Buckley, Peter F. 44
Bundren, J. Clark 80
Bunker, Mark T. 25
Buntinx, Erik 57, 76, 85
Burch, Daniel 57, 81
Burke, Ainsley 75
Burke, Jack D. 44
Burn, David 83
Busner, Joan 74
Bustillo, Juan 89
Buzhdygan, Tetyana 71
Bystritsky, Alexander 82
Calabrese, Joseph R. 55, 72, 76
Calarge, Chadi 86
Carlson, Berit 72, 82
Carpenter, Randall 86
Casey, Daniel 74
Cassidy, Kristin 82
Castagné, Vincent 76
Cater, Jacqueline 72
Chai, Xiaoqian 81
Chang, Kiki 72
Chang, Trina 74, 75
Chansard, Matthieu 75
Chavkin, Charles 67
Chawla, Jatinder 26, 81
Chen, Lei 88
Chen, Ying 76
Choukour, Moutaz 78
Chowdhury, Mohammad 82

Index

Citrome, Leslie 36, 78, 90
Classi, Peter 75
Coakley, Alice 81
Coffey, Barbara 77
Conley, Robert 88
Conroy, Carla 76
Cook, Ian 60, 75
Coppola, Danielle 89
Corena-McLeod, Maria 86
Cornelius, Jack 84
Correll, Christoph U. 47, 59, 60, 73, 88, 89
Crans, Gerald 82
Crystal, Steven 47
Cucchiaro, Josephine 71, 77, 78, 79, 89, 90
Culpepper, Larry 75
Cunningham, Kathryn A. 67
Cutler, Andrew 85
Daly, Ella 78, 79
Daniel, David G. 36, 71, 74, 90
Danielyan, Arman 26, 72
Daupinais, Deborah 72
Davis, John 90
Davis, Lori 73
Davis, Vicki 88
de Boer, Peter 78, 79
DeBonis, Daniel 87
de Chaffoy, Didier 85
De Francisco, Don 86
DeFries, Ashleigh 79
DeGiorgio, Christopher 75
DelBello, Melissa 72
Deliyannides, Deborah 76
DelIva, Mary Anne 75
Demartinis, Nicholas 90
DeRosier, Melissa 77
Detke, Holland 78, 79
Detke, Michael 87
Detweiler, Mark 87
Doraiswamy, P. Murali 32
dosReis, Susan 45
Douaihy, Antoine 84
Dries, Jean 71
Duan, Naihua 75
Dubé, Sanjay 75
Dunbar, Geoffrey 56, 85, 88
Dunlop, Boadie W. 37
Eccles, Martin 83
Edman, Suzanne 87
Ellis, Steven 75
Emslie, Graham J. 65, 73
Ereshefsky, Larry 90
Erickson, Craig 86
Erickson, Gregory 76
Essock, Susan 79
Eudicone, James 74, 82
Evans, Kenneth 66
Everitt, Amy 72
Evins, Eden 81
Fahim, Raafat 30
Farace, Elana 37
Farchione, Tiffany R. 25, 47
Faucett, James 83
Fava, Maurizio 56, 60, 61, 74, 75, 86
Fayyad, Rana 75
Fearer, Stephanie 81
Feeny, Norah 71
Fein, Elizabeth 76
Feldman, Gregory 86
Feldman, Peter 79, 88
First, Michael 78
Flavin, Karen 73
Forbes, Robert 72, 82, 85
Fortinsky, Paige 80
Fox, Kolleen 88
Frank, Ellen 69, 84
Friis, Rasmus 89
Frye, Mark 82
Fryling, Milo 78
Fu, Dong-Jing 79, 87
Fukuo, Yasuhisa 88
Furiak, Nicolas 79
Gabbay, Vilma 77
Gabrieli, John 81
Ganocy, Stephen 76
Gao, Joseph 85
Gao, Keming 72
Garibaldi, George 58
Geibel, Brooke 85
Geist, Cheri 75
Gelman, Gennady 88
Ghaffari, Manely 72
Gilbert, Alison 84
Giller, Earl 83

Ginsberg, Lawrence 86
Glick, Ira D. 35, 77
Goff, Donald 35
Goldberger, Celine 75
Gomez-Pinilla, Fernando 75
Gopal, Srihari 79, 89
Gorron, Natalia 86
Grannemann, Bruce 75
Grant, Jon 86
Greco IV, Nicholas 90
Greer, Tracy 75
Griffeth, Benjamin 81
Grinnell, Todd 80
Grosz, Daniel 86
Grunebaum, Michael 75
Guico-Pabia, Christine 75
Haas, Manuel 34
Haazen, Ludo 76, 85
Hackett, David 76
Hails, Katherine 86
Halls, Corinne 71
Harsh, Veronica 80
Hartoonian, Narineh 76
Harvey, Philip 70, 79, 88
Hassman, Howard 74
Hauser, Marta 26, 87
Hay, Justin 87
Heal, David 76
Hebden, Tony 74, 75
Hehman, Chris 77
Heinssen, Robert 58, 66
Hellerstein, David J. 37, 76
Hellings, Jessica 73
Henry, Mellissa 86
Henry, Michael 74, 83
Heres, Stephan 59
Herrmann, Nathan 73
Hessler, Martha 73
Hill, Lauren D. 25
Hilt, Dana 82
Hinds, Oliver 81
Hirschfeld, Robert 82
Hobart, Mary 85
Hobus, Joy 83
Hochfeld, Marla 78, 87, 90
Hosford, David 85, 88
Hough, David 79, 89
Howe, Meghan 72
Howland, Robert 73
Hsu, Jay 89, 90
Hunter, Aimee 75
Hunter, Brian 87
Husken, Gitta 78
Hwang, Eunhee 85
Inada, Toshiya 88
Iovieno, Nadia 26, 83
IsHak, Waguih 76
Isik, Rengin 76
Ivanova, Evgenia 79
Iwata, Nakao 88
Jackson, Richard 87
Jacobson, Leslie 56
Jain, Raka 81
Janssens, Luc 78, 79
Jayathilake, Karu 76
Jensen, J. Eric 83
Jensen, Peter S. 47
Jensen, Signe 89
Jeromin, Andreas 57
Jerrell, Jeanette 45
Jing, Yonghua 74, 75
Johnson, Bankole 29
Jones, Erin 71
Jones, Hendree 46
Joyner, Krystle 73
Kablinger, Anita 81
Kaiser, Thomas 54
Kalali, Amir 89
Kaliora, Styliani 26, 83
Kalsekar, Iftekar 74, 75
Kamiya, Toshikazu 77
Kane, John M. 32, 53, 59, 60, 88
Kaptchuk, Ted 61
Karayal, Onur 72, 82
Karcher, Keith 79
Kasari, Connie 46
Katz, Barbara 86
Kealoha, Chanel 76
Keefe, Richard 31, 88
Keller, Stephanie 71
Kelley, Ryan 72
Kelly, Megan 86
Kemp, David 76
Kennedy, Sidney H. 65
Kent, Justine 78, 79

Ketter, Terence A. 69, 72
Khan, Arif 83, 85
Khan, Shirin 83
Khin, Ni 59
Kim, Sanghyeon 88
King, Bryan 86
King, Jessica 73
Kinon, Bruce 88
Kirisci, Levent 84
Kishimoto, Taishiro 26, 88
Kishi, Taro 88
Kishon, Ronit 76
Knable, Michael 72
Knackstedt, Lori A. 67
Knapp, Penelope 47
Kobak, Kenneth 87
Koble, Jackie 78
Koenig, Gerhard 82
Kogan, Jane 89
Kohegyi, Eva 73
Kolluri, Sheela 72, 82
Konechnik, Thomas 75
Koola, Maju 26, 89
Kosten, Thomas 30, 81
Krishnan, Ranga 88
Krystal, John 33
Kryzhanovskaya, Ludmila 90
Kupfer, David J. 41, 84
Kurian, Benji 73
Kurlander, Jonathan 74, 75
Laezza, Fernanda 26, 71
Lal, Rakesh 81
Lanctôt, Krista 73
Lane, Alexandra 77
Lane, Rosanne 89
Lane, Sean 79
Lash, Steven 81
Lasser, Robert 85
Laubmeier, Kimberly 74
Lauriat, Tara 26, 83
Lauriello, John 44, 89
Lehman, Lauren 81
Leon, Andrew C. 25, 58
Leuchter, Andrew 75
Levenson, Jessica 84
Levin, Jennifer 82
Liang, Earvin 82
Liang, Yali 84
Lichtenberg, Pesach 83
Lieberman, Jeffrey 88
Liebowitz, Michael 57, 81, 85
Liechti, Stacy 79
Li, Jennifer 85
Lindsay, Jan 81
Li, Sherrie 72
Litten, Raye Z. 25, 29, 68
Little, Jessica 90
Liu-Seifert, Hong 79
Llorca, Pierre-Michel 78
Locatelli, Allison 77
Loebel, Antony 71, 73, 77, 78, 79, 89, 90
Longmire, Crystal Flynn 71
Lubaczewski, Shannon 84
Luther, James 73
Lydiard, Bruce 77
Mago, Rajnish 77
Mahajan, Rajeev 77
Maier, Philip 78
Mallinckrodt, Craig 36, 77
Malone, Richard 72
Mandel, Francine 72
Manji, Husseini 54
Mann, John 75
Mansuy, Lucilla 85
Manuel, Jennifer 79
Mao, Xiangling 77
Marchant, Barrie 71
Marcus, Sue M. 61, 62
Marshall, Randall 80
Maruff, Paul 49
Masand, Prakash 72
Mathis, Mitchell 34, 48, 69
Matschke, Kyle 84
Mattes, Jeffrey 31
Mattingly, Greg 87
Mayes, Taryn 73
McCann, David 30, 67
McConnell, Scott 78
McCracken, James 86
McDonald, Krysta 90
McDonnell, David 79
McElhiney, Martin 76
McEvoy, Joseph P. 44
McGlade, Erin 26, 77
McGrath, Patrick 30, 76

McIntyre, Roger 66, 72
McKay, James 46
McQuade, Robert 74, 75, 85
Mehra, Sunil 84
Mehra, Vishaal 83
Mehta, Pankaj 84
Melega, William 82
Mele, Linda 85
Melmed, Raun 86
Meltzer, Herbert 76
Meng, Xiangyi 78, 87, 90
Menlow, Nicole 73
Merlo-Pich, Emilio 60
Michelson, David 57
Micula-Gondek, Weronika 82
Mihalyo, Mark 89
Miller, David 83
Miller, Patrick 75
Mintzer, Jacobo 71
Mirocha, Jim 76
Modarress, MO 71
Montgomery, Stuart 74
Monti, Louis 81
Montoya, Iván D. 25
Morishita, Koji 77
Morita, Masahiko 77
Morris, David 73, 80
Morrissey, Judy 86
Mundt, James 73, 86
Murphy, Susan A. 46
Musgnung, Jeff 75
Myers, Amanda 70
Narrow, William E. 45
Nasrallah, Henry 77
Nelms, Heather 78
Nelson, Craig 37
Newcomer, John 70, 73, 78
Nichols, Alice 84
Nicol, Ginger 73
Nicolini, Humberto 81
Nielsen, David 81
Nielsen, Jimmi 26, 89
Nierenberg, Jay 84
Nietert, Paul 71
Nimgaonkar, Vishwajit 84
Noronha, Antonio 29
Nuamah, Isaac 79, 89
Nueten, Luc van 79
Obral, Sarah 76
Odlaug, Brian 86
Ogasa, Masaaki 73, 90
Oh, Paul 73
Okochi, Tomo 88
Olfson, Mark 59
Olsen, John 71
Ongur, Dost 55
Opler, Mark 73, 79
Oquendo, Maria 75
O'Shea, Donna 76
Oskooilar, Nader 86
Oslin, David 29
Ozaki, Norio 88
Pae, Chi-Un 84
Pal, Hemraj 81
Palumbo, Joseph 68, 79
Pandina, Gahan 89
Pandurangi, Ananda 73
Pangilinan, Maria 79
Papadopulos, Elizabeth 47
Papakostas, George 37, 56, 74, 75, 83
Pappadapulos, Elizabeth 72
Parks, Joseph 54
Patkar, Ashwin 84, 85
Pedersen, Cort A. 35
Pedrelli, Paola 86
Pelham, William E. 46
Perlis, Roy 69
Petkova, Eva 31
Petrides, Georgios 83
Phillips, Debra 78
Phillips, Glenn 73
Phillips, Katharine 86
Phillips, Mary 55
Pi, Bo 74
Pietrobon, Ricardo 88
Pikalov, Andrei 73, 77, 78, 79, 90
Pomara, Nunzio 84
Portland, Kimberly Blanchard 84
Posner, Kelly L. 36, 48
Post, Robert M. 66
Potkin, Steven 89, 90
Prasad, Soumya 84
Rabinowitz, Jonathan 35
Rahman, Zia 74, 82

Index

Ramey, Tanya 84
Rapaport, Mark H. 25, 76, 90
Rathmell, Barbara 86
Regier, Darrel A. 31, 44
Reimherr, Fred 71
Reiss, Allan 72
Remington, Gary 90
Remmerie, Bart 79, 89
Renshaw, Perry 74, 83
Rethorst, Chad 26, 76
Reyes, Tracy 73, 86
Richards, Cynthia 85
Richelson, Elliott 86
Riddle, Mark A. 65
Robinson, Donald 84
Robinson, Louise 83
Robinson, Rebecca 68
Robison, Reid 71
Rohling, Martin 49
Rosenbaum, Jerrold 31
Rosenthal, Norman 72, 81
Rothman, Brian 73
Rowley, Helen 76
Rubinow, David 80
Rucci, Paola 84
Rudolph, Richard 83
Ruggeri, Fabrizio 77
Ruse, Stacy 88
Rush, A. John 73
Sabrina, Young 76
Sachs, Gary S. 36, 74, 87
Sahay, Amar 26, 71
Sajatovic, Martha 82
Saleem, Mahwesh 73
Salinas, Eliseo 57, 82
Salloum, Ihsan 84
Salman, Ester 81
Sambunaris, Angelo 85
Samtani, Mahesh 79
Sanders, Erica 72
Sapra, Mamta 82
Sarma, Kaushik 78, 89
Sarocco, Phillip 73
Scahill, Lawrence 86
Schatzberg, Alan 70
Schechtman, Kenneth 73
Schmidt, Mark 78, 79
Schmidt, Peter 80
Schooler, Nina R. 25, 44, 81, 89
Schrader, Lara 75
Schuster, James 89
Schweiger, Julie 73
Schweizer, Edward 80
Segreti, Anthony 88
Sethi, Roopa 81, 82, 87
Severs, Joseph 78
Shaffer, David 45
Shavkunov, Alexander 71
Shear, Paula 72
Sheehan, John 79, 87
Shelton, Richard 74
Shen, Joan 83
Shen, Qi 83
Shungu, Dikoma 77
Sidtis, John 84
Siebenaler, Jean 74, 75
Sikich, LinMarie 66, 86
Silva, Raul 71
Silva, Robert 78, 90
Silverman, Daniel 75
Simonelli, Doreen 78
Simon, Neal 56, 84
Singh, Manpreet 26, 55, 72
Singh, Vivek 33
Siu, Cynthia 73, 77, 90
Skolnick, Phil 67
Skuban, Aleksandar 57, 85
Sliwa, Jennifer Kern 79
Smith, Patricia 73
Smith, Robert 35
Smolen, Harry 79
Sommers, David 66
Song, Guochen 88
Sorbero, Mark 89
Sousa, Sharon 74
Sparks, JonDavid 75
Srivastava, Shefali 72
Stahl, Stephen 78
Stanley, Barbara 48
Stauffer, Virginia 88, 90
Stein, Bradley 89
Stewart, Jessica 82
Stewart, Jonathan 76, 82
Stoeckel, Luke 26, 81
Stroup, Scott 79
Stuckey, Marilyn 71

Stutt, Andrea 83
Sugimura, Yoichiro 77
Susselman, Mary 75
Swardfager, Walter 26, 73
Swartz, Holly A. 25, 32
Swick, Danielle 77
Swift, Robert 29
Tamura, Roy 61, 77
Tanaka, Yoko 77
Tapp, Andre 31
Targum, Steven D. 36, 74, 90
Tariot, Pierre 82
Tatsuoka, Curtis 82
Tek, Cenk 35
Thase, Michael E. 37, 76, 84, 85
Thomas, Reena 87
Thome, Andrew 73
Tighe, Alex 81
Tohen, Mauricio 72
Tolliver, Bryan K. 55
Tong, My-Linh 86
Tourian, Karen 85
Tritsmans, Luc 78, 79
Trivedi, Madhukar H. 30, 55, 56, 73, 75, 85
Tsuchiya, Satoru 78
Turkoz, Ibrahim 87
Umeda, Tadashi 85
van den Broeck, Remi 76, 85
Vanderburg, Douglas 82
van Gerven, Joop 87
Vankirk, Kathryn 71
van Osselaer, Nancy 78, 79
Vanover, Kimberly E. 35
Veenstra-VanderWeele, Jeremy 26, 86
Velligan, Dawn 90
Verdoorn, Todd A. 32
Verma, Beeta 72
Veroff, Amy 49, 83
Vialet, Cecile 85
Vilhauer, Jennice 26, 76
Vitiello, Benedetto 30, 45, 65
Volkow, Nora D. 42
Wagner, Karen D. 65
Wahlsted, Claes 70
Walkup, John T. 65
Wang, Huali 83
Wang, Paul 86
Wang, Phillip S. 41, 60
Wang, Po 72
Warnock, Julia “Jill” 80
Warren, Kenneth 43
Watkins, Angela 74, 75
Watson, Susan 78
Webster, Maree 88
Weiden, Peter 78, 90
Welge, Jeffrey 72
Werner, Peter 85
Wesnes, Keith A. 49, 83
West, Susan 72
Whitfield-Gabrieli, Susan 81
Wilcox, Charles 86
Williams, Erika 71
Williams, Janet 87
Williams, Tiffany 82
Wilson, Melanie Elliott 78
Winchell, Celia 68
Winterstein, Almut 45
Wisniewski, Stephen 73
Wondmagegnehu, Eshetu 90
Wrishko, Rebecca 90
Wu, Johnna 83
Wu, Yan 79
Xie, Diqiong 86
Xu, Jane 77, 89, 90
Xu, Yimei 79
Yang, Larry 79
Yang, Ye 85
Yeung, Albert 74, 75, 86
Yildiz, Aysegul 33
Yingling, Michael 73
Yoo, Seung-Schik 82
Young, Allan H. 37, 66
Yurgelun-Todd, Deborah 77
Zalsman, Gil 73
Zammit, Gary 80
Zarate, Carlos 56
Zetterberg, Henrik 84
Zhang, Peter 85
Zimmerman, Mark 33
Zimmerman, Miriam 86
Zito, Julie M. 45
Zoellner, Lori 71
Zummo, Jacqueline 80

Notes

EMERGENCY INFORMATION SHEET

The ASCP Executive Office has developed the following information to assist you in case of an emergency. Please ensure that someone not attending the meeting with you has the following information:

Meeting Name: 51st Annual NCEDU Meeting
Meeting Location: Boca Raton Hotel, 501 East Camino Real, Boca Raton, Florida 33433
Hotel Phone Number: +1-561-447-3622
ASCP Executive Office Number: +1-615-649-3085
Additionally, your contact should have the following:

- Your cell phone number (if applicable)
- Your lodging information including room number
- Your transportation information

LOCAL INFORMATION

Nearest Urgent Care Facility: Health South Urgent Care 1786 Boca Raton Blvd Boca Raton, FL 33434 (561) 368-6920	Nearest Hospital: Boca Raton Community Hospital 800 Meadows Road Boca Raton, FL 33431 (561) 395-7100

General Safety Reminders:

- Don't leave bags and briefcases unattended during meeting sessions. Be aware the conference bags all look alike and someone could easily pick yours up by mistake.
- Verify walking/jogging routes with the hotel concierge.
- Review hotel safety information posted on the inside of the sleeping room door (including emergency exits and where fire extinguishers are located).
- Should an emergency situation arise, contact your family as soon as possible.

In case of fire:

The fire alarm sound is followed by an announcement urging you to vacate the facility. Should this occur, do not attempt to use the elevators. Emergency exits are marked with illuminated EXIT signs. In case of fire, ASCP and hotel staff will be available to assist you in exiting the facility.

In case of medical emergency:

If you are in your hotel room or anywhere on hotel property, dial extension 49, this will connect you directly into the hotel dispatcher who will disperse security and EMS personnel. If you are attending a meeting event, contact the nearest hotel or ASCP staff person. (If this is not possible, have someone else do it for you.) Please make sure someone informs the ASCP staff of the emergency.

In case of a weather-related emergency (i.e., tornado, hurricane, earthquake, etc):

The ASCP Executive Office continually monitor local weather situations and will alert you to any potential emergencies. Should these arise during a meeting event the ASCP and hotel staff will direct you to a pre-determined safe location. Should these emergencies interfere with your transportation or hotel room stay; the ASCP staff will assist you in altering your arrangements. Should these emergencies arise during non-meeting events the hotel staff will direct you to a pre-determined safe location. In case of emergency evacuation, the nearest emergency shelter would likely be located at Boca Raton Community High School, 1501 NW 15th Court, Boca Raton, FL, 33486, 561-338-1420 (location is confirmed at the time of the emergency). Please make your way from your room to this location as soon as possible.

In case of other emergency situations:

The ASCP staff works closely with the hotel staff and city officials to monitor all potential situations. The hotel has an emergency evacuation plan in place. Should a situation arise, ASCP staff will provide the appropriate information regarding emergency shelter locations, medical care, transportation, etc.

ASCP
American Society of
Clinical Psychopharmacology
www.ascpp.org

ASCP Executive Office
5034A Thoroughbred Lane
Brentwood, Tennessee 37027

phone: 615-649-3085
fax: 615-523-1715
email: info@ascpp.org